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ABSTRACT
With knowledge of the human genome increasing constantly we are continually faced
with new and potentially groundbreaking methods for managing, treating and/or
identifying diseases and predisposition to diseases and conditions at a genetic level.
The human cytochrome P450 (CYP) super-family of genes code for enzymes that can
participate in metabolism of drugs and foreign chemicals and in steroid synthesis and
metabolism. Mutations in these genes may contribute to clinically relevant diseases.
In this study, the effects of mutations within four CYP genes were evaluated in two
South African disease groups - variegate porphyria and breast cancer.
Variegate porphyria (VP) has an unusually high incidence in South Africa due to the
R59W founder mutation in the protoporphyrinogen oxidase (PPOX) gene that causes
a disruption in the haem biosynthetic pathway. VP presents with variable clinical
symptoms and has a relatively low penetrance. It is expected that environmental
factors and modifier genes play a role in the clinical expression of VP. CYP genes
are implicated as candidate modifier genes for the expression of VP due to the
function they have in metabolising many drugs contraindicated in porphyria patients,
and the necessity of haem binding to the apoprotein to produce a functional CYP
enzyme. This is the first study to investigate CYPs as possible modifier genes for VP
clinical expression. Six CYP polymorphisms (CYPIAlml, CYPIAlm2, CYPIA2 -
734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4), associated with four CYP
loci, were genotyped in a VP population and a suitable control population. The
results observed are suggestive of CYPIAlml and CYPIBI playing a role as
modifiers for the clinical expression of VP as they were significantly associated
(P<O.05) with the presence ofVP related symptoms.
Breast cancer is one of the leading causes of death in women due to cancer. It is
believed that breast cancer may be the result of co-participation between common
DNA alterations and environmental exposures. Polymorphisms in enzymes involved
with the metabolism of environmental exposures, such as the cytochrome P450
enzymes, are therefore expected to play an aetiological role in breast cancer. Two
groups of South African breast cancer patients (Caucasian and of mixed ancestry) and
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population-matched controls were genotyped for four CYP polymorphisms
(CYPIAlml, CYPIAlm2, CYPIA2 -734 C>A and CYPIBI 8372 A>C). This
represents the first investigation of the potential role of CYPs as breast cancer risk
modifiers in the two South African populations. Significant differences were
observed (P<O.003) in genotype and allele frequencies between the breast cancer
patients and controls for the CYPIBI 8372 A>C polymorphism in the population of
mixed ancestry. Vast differences in allele frequencies were also observed between
the two groups of breast cancer populations. These results emphasize the importance
of population-based risk assessment when genetic testing and counselling for complex
disease susceptibility is offered.
The results of this study provide the first evidence suggesting a role for CYPs in
modifying the clinical expression of VP and in acting as risk factors for developing
breast cancer in a South African population.
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OPSOMMING
Met die konstante toename van kennis oor die mensgenoom kom ons voortdurend te
staan voor nuwe metodes vir die beheer, behandeling en/of identifikasie van siektes
en vatbaarheid vir siektes op 'n genetiese vlak. Die mens sitochroom P450 geen-
superfamilie kodeer vir ensieme betrokke in die metabolisme van medisyne en ander
chemiese stowwe en steroïed-sintese en -metabolisme. Mutasies in hierdie gene kan
'n bydrae lewer tot kliniese relevante siektes. In hierdie studie is die effek van
mutasies in vier sitochroom gene bestudeer in twee Suid-Afrikaanse siekte groepe,
variegate porfirie en borskanker.
Variegate porfirie (VP) het 'n besonderse hoë frekwensie in Suid-Afrika as gevolg
van die R59W stigter-mutasie in die protoporfirinogeen oksidase (PPOX) geen.
Hierdie mutasie lei tot 'n versteuring in die heem biosintese padweg. VP presenteer
met variërende kliniese simptome en het 'n betreklike lae penetrasie. Daar word
vermoed dat omgewingsfaktore en kandidaat modifiserende gene 'n rol speel in die
kliniese beeld van VP. Sitochroom P450 gene is geïdentifiseer as kandidaat
modifiserende gene as gevolg van hulle rol in die metabolisme van verbode medikasie
vir porfirie pasiënte, asook die binding van heem aan die apoproteïen wat noodsaaklik
is vir die produksie van funksionele sitochroom P450 ensiem. Hierdie is die eerste
studie wat sitochroom P450 gene as moontlike modifiserende gene vir die kliniese
uitdrukking van VP ondersoek. Ses sitochroom P450 polimorfismes (CYPIAlml,
CYPIAlm2, CYPIA2 -734 C>A, CYPIBI 8372 A>C, CYP2D6*3, CYP2D6*4) is
ondersoek in beide 'n VP populasie en 'n geskikte kontrole populasie. Die resultate
suggereer 'n rol vir CYPIAlml en CYPIBI in die modifisering van die kliniese
uitdrukking van VP aangesien hulle betekenisvolle assosiasie (P<O.05) met die
voorkoms van VP-verwante simptome getoon het.
Borskanker IS een van die vernaamste oorsake van kankersterftes onder vroue.
Borskanker IS waarskynlik die resultaat van interaksie tussen algemene DNS-
veranderinge en omgewings-blootstelling. Daar word dus verwag dat polimorfismes
in ensieme betrokke by die metabolisme van omgewingselemente, soos byvoorbeeld
die sitochroom P450 ensieme, 'n etiolgiese rol in borskanker sal speel. Die genotipes
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van twee groepe Suid-Afrikaanse borskanker lyers (Kaukasiërs en van gemengde
herkoms) en populasie-passende kontroles is bepaal vir vier sitochroom P450
polimorfismes (CYPIAlml, CYPIAlm2, CYPIA2 -734 C>A, CYPIBI 8372 A>C).
Hierdie studie verteenwordig die eerste ondersoek na die potensiële rol van
sitochroom P450s as risiko-modifiserende faktore vir borskanker in die twee
populasies. Betekenisvolle verskille (P<O.003) in genotipe en allele frekwensies is
waargeneem tussen die borskanker lyers en kontroles vir die CYPIBI 8372 A>C
polimorfisme in die gemengde herkoms populasie. Beduidende verskille in alleel
frekwensies is ook waargeneem tussen die twee borskanker populasies. Hierdie
resultate beklemtoon die belangrikheid van populasie gebaseerde risiko-beraming
wanneer genetiese toetse en voorligting vir komplekse siekte-vatbaarheid aangebied
word.
Die resultate van hierdie studie bied die eerste getuienis dat sitochroom P450s 'n rol
kan speel in die modifisering van die kliniese beeld van VP en ook kan optree as as
risiko faktore vir die ontwikkeling van borskanker in 'n Suid-Afrikaanse populasie.
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CHAPTER ONE
CHAPTER ONE
INTRODUCTION
The multitude of current and envisioned research developments m the fields of
genetic information and genetic technologies possess the ability to fundamentally
redefine medicine within many of our lifetimes. Major transformations in many
aspects of healthcare ranging from diagnostics, disease management and treatment
options will be a direct/indirect result of breakthroughs in genetics. Change such as
this is inevitable, but this change will not occur over night, rather it will be gradual
and will take on multiple forms.
With knowledge of the human genome increasing constantly we are continually faced
with new and potentially groundbreaking methods for managing, treating and/or
identifying diseases and predisposition to diseases and conditions at a genetic level.
Some of these methods have already been realised as seen with genetic tests for
predisposition, carrier status determination and diagnosis of a multitude of diseases
including, variegate porphyria (protoporphyringen oxidase gene (PPOX» and breast
cancer (BReAl and BRCA2). Information generated from the human genome about
genes and the resulting technologies are moving healthcare into new territory. This
forward movement will see demands of the public increasing for access to new tests,
drugs and treatment, resulting in growth of public expectations from medicine. This
will in turn impact on research efforts in genetics, resulting in the introduction of new
interventions, diagnostics and treatments into direct healthcare delivery.
Genetics has played a role in medicine for a long time, and has been acknowledged
for the positive contributions it has made. The ability genetic tests hold for early
diagnosis, carrier status determination and predisposition of diseases opens the door to
lifestyle changes that may possess the ability to alter the course of the disease and
reduce its onset hereby improving health. Genetic tests are also advancing treatments
and other health interventions. All this said, one must not loose sight of the relative
role genetics plays in disease management. A risk associated with progress in
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CHAPTER ONE
genetics is the tendency for society to attribute an almost mystical power to genetics,
and consequently forget the important role environmental factors including housing,
nutrition and employment play in shaping health.
The pharmaceutical industry is an example of an area where genetics and
environmental factors are encountered together. This industry has evolved from
chemically-driven production to genotype-driven analysis of patient subpopulations
(Miller, 1998). It makes use of advances in genetic technologies that allow for tailor
made treatments that are specific to disease subtypes and individuals. The availability
of new drugs, the identification of alternate drugs, and the adjustment of drug dosage
all aim to reduce the risk of adverse drug reactions. The identification of further drug
targets allows for the development of additional specific drug therapies that may hold
more benefits for the patients. Developments such as these allow for betier informed,
cost-effective disease management practices. Genetic research therefore, continually
helps shape the development of assessment tools allowing increasingly more effective
treatments that are designed to be genetically compatible with the person that is in
need of them.
New techniques, diagnostics and treatments bring hope, but are also burdened with
many challenges, some unique to the field of genetics. It is estimated that the birth
incidence of infants with trivial or easily correctable congenital disorders is about 25-
60/1000. The birth incidence of severe congenital disorders that cause early death or
life-long chronic disease ranges from 14/1000 in developed countries to 43/1000 in
developing countries (WHO, Human Genetics Programme, 2002). It is estimated that
15% of all cancers have an inherited susceptibility (Schneider, 1994). It is therefore
highly likely that a significant proportion of the South African population will
experience a disease with some form of genetic component during their lifetime.
Genetic research and technology therefore has the potential to improve healthcare in a
large fraction of the South African population. The network of genes that govern
drug responses in humans will have to be well defined to enable more accurately
optimised drug therapy based on each patient's ability to metabolise, transport and
respond to medications.
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CHAPTER ONE
To assist in fulfilling the promises of pharmacogenomics clinical and epidemiological
studies are needed to assess how drug response varies among individuals with
different genotypes, the prevalence of the genotypes in the population and relevant
subpopulations and the degree of interaction between environmental and genetic
factors in influencing drug response. The creation of population-based databases
providing information necessary for the successful application of pharmacogenomics
in the practice of medicine and public health is essential.
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CHAPTER TWO
LITERATURE REVIEW
2.1 PHARMACOGENETICSIPHARMACOGENOMICS
Pharmacogenetics is the study of variability in drug response due to heredity, and
includes research of genetic polymorphism in genes encoding drug transporters, drug
metabolising enzymes and drug receptors. It encompasses a combination of the fields
of genetics, pharmacology and biochemistry. Pharmacogenomics on the other hand is
a broader, more recent term that includes the newer sciences of molecular biology,
genomics, bioinformaties and their associated technologies (Norton, 2001).
Pharmacogenomics focuses on novel drug development, as disease genes become
known. The purpose of this field of research is to understand the underlying reasons
for differential human response to xenobiotics, to reduce the advent of adverse drug
reactions and to provide individualised drug therapy. The terms pharmacogenetics
and pharmacogenomics are often used inter-changeably. Pharmacokinetics describes
the time course of a drug's actions, i.e. the time to onset and the duration of the drug's
effects (Julien, 1996). Molecular pharmacogenetics started with the cloning and
characterisation of cytochrome P450 2D6 (CYP2D6). Molecular pharmacogenetics
now encompasses the study of many other human genes including genes coding for
drug receptors, drug metabolising enzymes and drug transporters.
Early in the 1950s researchers realised that some adverse drug reactions (ADRs)
could be caused by genetically determined variations in enzyme activity. The
occurrence of ADRs were the clinical events that revealed to researchers genetic
variants of drug metabolising enzymes or drug targets (Meyer, 2000). In this way the
role of genetic polymorphisms in drug response were accidentally discovered, by
observing that some patients and/or volunteers experienced unpleasant reactions when
administered standard doses of a drug.
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Genetic Polymorphism
A genetic polymorphism exists when an allelic variant (the alteration must be stable
within the population) occurs within a human population at a frequency of 1% or
more. The number of single nucleotide polymorphisms (SNPs) present in the human
genome is estimated to be approximately three million (Roses, 2002). The majority
of these however, have no function and are located between genes, so called
intergenic or random SNPs (iSNPs/rSNPs). Intergenic SNPs are most likely the result
of 4-fold degenerate sites (Nebert, 1999). Single nucleotide polymorphisms present
in introns and upstream regulatory regions (non-coding regions) are perigenic SNPs
(PSNPs). Perigenie SNPs also include silent codon mutations and changes in the
noncoding regions of the mRNA and at least 100 bp 3' of the last exon. Those
present in coding regions are so called coding SNPs (cSNPs). Coding SNPs may
cause an alteration in the amino acid sequence of the encoded protein that mayor may
not result in an alteration in the function of the protein. A genetic polymorphism is
clinically relevant when it meets with certain drug-related criteria. These criteria
include narrow therapeutic range or large inter-individual variation in kinetics or
suspicion of overdose (Meyer, 2000).
This brings up the concept of wild-type (normal) allele designation. When
considering the obvious ethnic differences in drug metabolising gene polymorphisms,
the designation of wild-type seems arbitrary (Nebert, 1999) and the definition of
wildtype becomes somewhat flawed when one considers how allelic frequencies
differ between different ethnic populations (Yan et al., 2000).
Response to Medication
Mutations found in drug metabolising enzyme genes, drug receptor genes and drug
transporter genes and the effect of the mutations on the protein product varies from
having no effect, to decreased activity or absence of enzyme. Gene duplications
result in increased enzyme/enzyme activity (Ingelman-Sundberg, 2001). Mutations in
drug metabolising enzymes allow one to classify patients into one of four groups
(patients have to be classified for each gene that is genotyped): extensive
metabolisers who are homozygous or heterozygous for the wild type allele,
intermediate metabolisers who have two mutations resulting in decreased enzyme
5
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO
activity, poor metabolisers who carry two loss-of-function mutations and ultra rapid
metabolisers who have duplicated or multi-duplicated copies of the gene (Meyer,
2000). The presence of defective alleles results in adverse drug reactions in patients
while a lack of drug efficacy is observed due to ultra rapid metabolism. Table 2.01
highlights the differences observed in drug metabolism between poor and ultra rapid
metabolisers.
Induction and inhibition of drug transport/metabolism is influenced by environmental
factors while aging is known to decrease capacity for drug metabolism and capacity to
induce drug metabolising enzymes. It is very difficult to disentangle the contribution
of environmental and genetic factors in an individual patient.
Table 2.01: The clinical importance of the different phenotypes with respect to
drug metabolism
Poor Metabolisers Ultra Rapid Metabolisers
• Diminished first pass metabolism,
• Lack of therapeutic effect at standard
increased bioavailability, exaggerated
doses
response
• Diminished drug elimination, side
• Too much of the active metabolite
effects or toxic effects
• The therapeutic metabolite is not • Explanation for suspected bad
formed, loss of therapeutic efficacy compliance
(lngelman-Sundberg, 1998)
Although there are many mutations present within the genes involved with drug
transport, drug metabolism and drug receptors, only a few may prove to be common.
When analysing an individual's response to medication, one has to take into account
that many gene products are involved in drug disposition and drug action. One
therefore has to take primary genes, modifier genes and environmental factors into
consideration. Differences in allele frequencies and in functional defects are observed
for different ethnic groups (Johansson et al., 1994, Ingelman-Sundberg et al., 1999,
Evans and Johnson, 2001, Ingelman-Sundberg, 2001). This ethnic diversity (gene
geography) suggests that one needs to take ethnic origin into account as well when
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performing pharmacogenomic studies and when initiating drug therapy. It has been
estimated that 85% of a patients response to a drug is due to genetics (Anonymous,
1998) and that a major cause of ADRs is an individuals genetic predisposition (Spear
et al., 2001).
Evans and ReIling (1999) have reviewed many of the genes that show association
with a specific response to a drug. These include genes encoding proteins that are
involved with drug absorption, distribution, metabolism and elimination, genes
encoding drug targets and some genes whose relation to drugs are yet unknown.
Their findings indicate that these genes demonstrate polymorphism and that the major
allele encodes the normal protein while the mutant alleles encode proteins with varied
function. The function of the "mutant" protein is usually just reduced or absent
however, it has been shown that increased function may also result. Altered protein
function is very rare.
2.1.1 Application of Pharmacogenomics
Pharmacogenomics has the potential to revolutionise drug therapy by facilitating both
choice and dosage of drug and the development of superior and safer therapies, as
summarised in Table 2.02. As population specific data regarding the structure of
genes and regulatory pathways that may cause altered response is generated by
pharmacogenomic research, improvement of diagnosis and clinical care will be
promoted (Weber, 2001). The advantage ofpharmacogenomic testing is simply that a
single DNA test performed once in a lifetime has the potential of identifying
predisposition of patients to at least the extreme phenotypes. The most significant
application of pharmacogenomics lies in the development of sensitive, specific
diagnostic tests for the identification of specific genetic changes responsible for
genetic diversity of human drug response (Norton, 2001, Weber, 2001).
The development of these diagnostic tests has been made possible by the vast array of
research into novel molecular genetic techniques. The development of analytical
techniques capable of increasing the speed of sequencing, mapping and human gene
identification have allowed large amounts of data to be collected from relatively few
experiments. These techniques are being used in developmental and physiological
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pathway elucidation, and for tracking perturbations in gene activities and patterns of
gene expression in cancer and other pathological conditions (Lockhart and Winzeler,
2000, Mir and Southern, 2000). Genetic tests have proved to be formidable forces in
areas of disease diagnosis, diagnosis confirmation and genetic disease predisposition
identification. Genetic tests are unique in that they are able to confirm the existence
of a disease or predisposition to a disease in asymptomatic individuals. Various
degrees of accuracy are observed between the different tests. At present there are at
least 877 genetic tests available internationally for genetic disorders in adults, children
and fetuses (Ontario Provincial Advisory Committee, 2001). The number of genetic
tests developed to detect genetic disorders is expected to increase dramatically in the
next few years with the vast amount of gene and single nucleotide polymorphisms
being identified (Oak Ridge National Laboratory, 2001). Molecular genetic
techniques have also found application in screening populations for polymorphisms
suspected of playing a role in drug susceptibility and for screening drug candidates for
new therapies (Weber, 2001).
Table 2.02: The Scope and Anticipated Benefits of Pharmacogenomics
Scope Benefits
• Identification and characterisation of
• Advanced screening for diseases
candidate genes and polymorphisms
• Improvements in drug discovery and
approval
• Correlation of polymorphism with
• Superior, safer drugs
therapy, clinical outcomes and drug
• Improved vaccines
effects
• Development of molecular genetic
• More powerful, individualised drugs
tests for drug selection and for
• Quicker response
predicting drug response
• Development of molecular genetic
• More accurate drug dosing
tests for dosing based on genotype or
• Minimising adverse drug reactions
gene expression
OUTCOME: Decreased cost of health care
(Norton, 2001, Knowledgene, 2001)
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Laboratory models have the potential to be very informative regarding
pharmacological and toxicological consequences of human conditions that we are
unable to study in human models for ethical and/or methodological reasons.
Development of inbred mouse strains, as well as recombinant, congenic and
recombinant-congenic inbred mouse strains have all aided research of this nature.
Mouse models have greatly increased our knowledge and understanding of metabolic,
genetic, developmental, toxicological and molecular genetic aspects of human
conditions (Goodman, 2002, Botta et al., 2001, Calvisi et aI., 2001, Aronson, 1999,
Licastro et al., 1999).
Another application of pharmacogenomics is gene therapy which targets specific
genetic mutations with the aim of correcting or deleting them. Gene therapy differs
from conventional therapy in that it aims to "treat" the DNA underlying the problem
rather than the symptoms caused by the disease. It is currently thought that gene
therapy has the ability to successfully treat monogenic disorders rather than polygenic
disorders. In monogenic disorders identification of targets for treatment is simpler
than target identification in diseases caused by the interaction of many genetic factors.
Somatic cell line gene therapy is successfully in progress (Mackesen et al., 1997,
Ontario Provincial Advisory Committee, 2001). Research into similar therapy for
germ cell lines is underway - implications for future generations need to be carefully
assessed. Gene therapy holds the promise for treating diseases that cause great pain
and suffering for the patients that conventional therapies are unable to treat. Gene
therapy may also have the ability to alter the chance that a person will develop a
disease (Science Daily, 2001).
The need for high capacity, high throughput tests for enhancing pharmacogenomic
research led to the use of and increased demand for the DNA microarray. This
technique exploits the sequence complementarity of the two strands forming the DNA
duplex (Southern et al., 1999). DNA sampling, genetic research and the field of
information technology fused to enhance the development of a DNA chip, which uses
microchip technology to accelerate genetics studies. DNA chip technology enables
the monitoring of therapy effectiveness and the investigation of complex interactions,
dependencies and information that flow between genes (Debouck and Goodfellow,
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1999). The number of adverse drug reactions could be greatly reduced and the
efficacy of antibiotic prescription greatly increased as DNA chip technology is
integrated into pharmacogenetics (Ontario Provincial Advisory Committee, 2001).
By increasing our knowledge of the effects different drugs have on gene expression
throughout the entire genome, insufficient and adverse drug reactions can be greatly
reduced by pharmacogenomics. If even partial fulfilment of the promise of
pharmacogenomics is realised, it will represent progress of a very significant nature.
2.1.2 Adverse Drug Reactions and Effectiveness of Drug Therapy
Adverse drug reactions have major implications for human health and for healthcare.
Patients may suffer adverse drug reactions for various reasons, including misdosing,
drug-drug interactions, drug allergies, medication errors, the patient's age and
ethnicity, renal and liver function, other disease factors and lifestyle variables such as
smoking and alcohol consumption. Hurwitz (1969) found, in a pioneering survey,
that the incidence of adverse drug reactions in patients admitted to an acute care
hospital, more than tripled in patients older than 70 years of age. Specific drug
metaboliser phenotypes have been linked to several adverse drug reactions (Evans and
Johnson, 2001). These inherited factors affect the kinetics and dynamics of many
drugs as increased or decreased metabolism has the ability to change the
concentrations of the drug as well as its active, inactive or toxic metabolites (Meyer,
2000). Genetic variations also have the potential to produce unexpected drug effects
or alter the clinical response and frequency of side effects if the polymorphism is
located in a gene encoding a drug target (Meyer, 2000). Determining the extent of
drug dose alteration for poor or ultra rapid metabolisers is a product of the
quantitative role of the effect of the drug metabolising enzyme and the drug uptake
mechanism in the overall kinetics of a drug and the agent's therapeutic range (Meyer,
2000). Six different types of ADRs have been described to date (refer to Table 2.03)
(University of Cape Town, 2002).
In 1994, over one and a half million hospital admissions in the United States of
America were due to adverse drug reactions (Spear et al., 2001). As many as two
million hospitalised patients in the United States of America experience adverse drug
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reactions per annum (Norton, 2001). The occurrence of fatal ADRs to medications
that are beneficial to others results in the death of approximately one hundred
thousand inpatients per annum in hospitals around the United States of America
(Lazarou, 1998, Meyer, 2000, Spear et al., 2001). This ranks ADRs as the forth to
sixth leading cause of death in hospital inpatients in the USA (Nebert, 1999, Meyer,
2000, Spear et al., 2001). Although similar data regarding ADRs in South African
hospitals is not currently available, there is nothing to suggest that the situation is any
different here.
Table 2.03: The six different types of adverse drug reactions described
Type Description
A Augmented (dose related), e.g. hypotension with a beta blocker
B Bizzare (non-dose related), e.g. anaphylaxis after penicillin injection
C Continuous (long term), e.g. osteoporosis with oral steroids
D Delayed (lag time), e.g. teratogenic effect with anti-convulsants
E Ending of use (withdrawal), e.g. withdrawal syndrome with benzodiazepines
F Failure of efficacy (no response), e.g. resistance to antibiotics
(University of Cape Town, 2002)
2.2 DRUG TRANSPORTERS, DRUG METABOLISING
ENZYMES AND DRUG RECEPTORS
Due to the great significance of drug transporters, drug metabolising enzymes and
drug receptors in pharmacological reactions they have been the subjects of many
pharmacogenomic research projects. Identifying the genetic variation within the
genes encoding these very important proteins is absolutely necessary if successful,
optimal drug treatment for all is going to be realised.
2.2.1 Drug Transporters
The role of membrane transporters in drug effects has generated much interest and yet
the relevant transporters for most drugs remain unknown (Yan and Sadée, 2000).
This is due to the fact that even if a transporter is known to interact with a specific
drug it remains unclear if other, yet unknown transporters may too recognise the same
drug. A primary goal of drug discovery and development is to understand which
11
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO
transporters recognise which drugs and which of these transporters can be exploited to
target and transport new drugs to the intended tissue within the body (Yan and Sadée,
2000). The intestine, blood brain barrier, central nervous system cells, intestinal cells
and the kidney membranes are the locations in which many drug transporters are
found. Many of these transporters are members of the adenosine triphosphate (ATP)-
binding-cassette (ABC) family and include P-glycoprotein, (P-gp, a multidrug efflux
pump) and multi-drug resistance proteins (MRP 1-6). Drug transporters are either Na+
or H+-coupled.
Polymorphisms have been found within some of the genes encoding transport
proteins, however, the importance of these polymorphisms in vivo is yet to be fully
understood (Evans and Johnson, 2001). Polymorphisms within these genes may
affect drug absorption, distribution, elimination, and tissue targeting. Arranz et al.
(2000) has identified six genetic polymorphisms within four genes encoding
neurotransmitters that are linked to clozapine drug response in schizophrenia
sufferers. Hoffmeyer et al. (2000) identified 15 polymorphisms in the human MDR1
(multi drug resistance P-glycoprotein) gene in a Caucasian study population. One of
these polymorphisms, a CIT in exon 26 showed a statistically significant correlation
with P-glycoprotein expression levels and activity. Resistance of human cells to
anticancer drugs is commonly associated with high expression of the multidrug
resistance P-glycoprotein (Gottesman et al., 1995) and the multi drug resistance-
associated protein (MRPl) (Hipfner et al., 1999).
Results of studies by Borst et al. (2000), Hoffmeyer et al. (2000), Cascorbi et al.
(2001) and Glatt et al. (2001) indicate that the field of polymorphic drug transporters
is a very important field. Ingelman-Sundberg (2001) is of the opinion that the effect
of mutations in drug transporters, on pharmacokinetics, will in many cases be more
difficult to interpret and will be of a smaller magnitude than that of polymorphic drug
metabolising enzymes. Application of micro array gene technology to analyse
membrane transporters may help determine tissue expression and allelic distributions
on an individual basis (Evans and Relling, 1999). The largest problem facing
researchers is, however, the determination of relevant transporters, not only because
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of the multitude of genes, but also because of the remarkable structural and functional
heterogeneity observed among transporters.
2.2.2 Drug Metabolising Enzymes
Drug metabolising enzymes are generally believed to have evolved as a consequence
of the interaction between plants and animals (Schuler, 1996). In order for plants to
defend themselves against predation and to enable them to synthesize secondary
metabolites for their reproductive cycle, plants require constantly evolving
biosynthetic pathways. Plants respond to predation by animals by evolving new
genes that synthesize toxic metabolites, forcing the animals to evolve new drug
metabolising genes in order to survive (Schuler, 1996, Ingelman-Sundberg et al.,
1999).
Xenobiotic metabolism can roughly be divided into two phases. Phase I is
characterised by the chemical modification of the compound by addition of a polar
functional group (Gonzalez and Nebert, 1990, lyer and Sinz, 1999) that can be used to
attach a conjugate. The compound in this form can then be excreted from the
kidneys, in the urine as the addition of the conjugate makes the modified compound
more water soluble. A hydroxyl group is frequently added in Phase I of drug
metabolism by many cytochrome P450s. This hydroxyl then serves as a site for
further modifications during phase II of drug metabolism which is typified by
conjugation of the primary metabolites further enhancing their polarity (lyer and Sinz,
1999). If activation is required to precede toxic response, it will more likely result
from phase I metabolism. However, it has recently been shown that phase II
conjugating metabolism can playa predominantlhighly significant role in determining
the response to the toxic xenobiotic administered as they are implicated in the
detoxification of such products (lngleman-Sundberg, 1998). These two sets of
enzymes, alone or in combination are responsible for generating metabolites that are
readily excretible (lyer and Sinz, 1999). Multiple xenobiotic-metabolising enzymes
with variable and fractionally overlapping catalytic properties are involved with the
elimination of lipophilic xenobiotics to avoid their accumulation in cells and tissues
(Guengerich, 1992, Nebert et al., 1996).
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Molecular mechanisms of inactivation for drug metabolising enzymes include splice
site mutations which result in exon skipping (cytochrome P450 19 (CYP19),
dihydropyrimidine dehydrogenase (DPD)), gene duplication (CYP2D6), enhanced
proteolysis (thiopurinemethyl transferase (I'PMIJ), altered promoter functions
(cytochrome P450 2A5 (CYP2A5)), critical amino acid substitutions (N-
acetyltransferase (NAT-2), CYP2D6, cytochrome P450 2C19 (CYP2C19),
cytochrome P450 2C9 (CYP2C9)), or large gene deletions (glutathione transferase
Ml (GSTMl), CYP2D6). Gene duplication (CYP2D6) results in the opposite
situation, that of enhanced activity of drug metabolising enzymes (Evans and
Johnson, 2001). The majority of gene duplications occurred as animals became
terrestrial, due to dietary selection pressure (plant toxins are speculated to have had a
major influence) (Ingelman-Sundberg et al., 1999). It is expected that no selection in
constitution of cytochrome P450s is expected to occur due to cancer caused by
pollution as cancer usually occurs after the human reproductive cycle (Ingelman-
Sundberg et al., 1999). Gene duplication can only occur if it offers an advantage to
the organism (Clark, 1994).
2.2.2.1 Phase One Metabolising Enzymes
Many phase I enzymes exhibit functional polymorphism that can result in increased
pharmacologic effects for medications that are inactivated by these enzymes. These
include tricyclic antidepressants (CYP2D6) (Dahl and Bertilsson, 1993), fluoxetine
(CYP2D6) (Sallee et al., 2000), warfarin (CYP2C9) (Aithal et al., 1999), 5-
fluorouracil and dihydropyrimidine dehydrogenase (Gonzalez and Femandez-
Salguero, 1995). Cytochrome P450 enzyme phase I metabolism converts many
compounds to reactive, electrophilic, water-soluble intermediates, some of which can
damage DNA (Hande, 1992, Raunio et al., 1995, Smith et al., 1995, Sonnichsen et al.,
1995).
2.2.2.1.1 Cytochrome P450 (CYP)
Cytochrome P450 comprise a large super-family of brightly coloured haem thiolate
proteins that are of critical importance in the detoxification or activation of a large
number of foreign hydrophobic compounds, including therapeutic drugs, chemical
carcinogens and environmental pollutants (Guengerich and Shimada, 1991, Gonzalez
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and Gelboin, 1994). They are responsible for catabolising compounds to provide a
carbon source and for the synthesis of biologically active compounds including
steroids, prostaglandins and arachidonate metabolites (Graham and Peterson, 1999).
All organisms, protists to mammals, possess cytochrome P450 enzymes (Nelson et
al., 1996, Graham and Peterson, 1999).
Cytochrome P450 enzymes are the most important drug-metabolising enzymes in
humans and therefore playa major role in many drug-drug and drug-food interactions.
Cytochrome P450 enzyme reactions usually function to inactivate a drug but
occasionally they may induce activation of the drug (National Community
Pharmacists Association, 2001). All the compounds metabolised by CYP enzymes
have one characteristic in common, they are all almost insoluble in water, and
therefore have the tendency to accumulate in the membranes and other structures
within cells and tissues which contain little/no water (American Medical Association,
2001). The extent of drug metabolism by a specific cytochrome P450 isoform is
determined by the affinity of the substrate-enzyme complex and the relative
abundance of the particular CYP enzyme in relation to the total amount of CYP in the
liver (Ózdemir et al., 2001). Genetic control of levels of individual CYP expression
could influence toxicity of drugs via an increase of CYP (Firozi et al., 1996).
The key to understanding CYPs' importance lies in increasing our knowledge of their
location and function. CYP enzymes are found throughout the human body but are
most active in tissues that frequently come into contact with external materials e.g.
liver, lung, skin, gut and kidneys (American Medical Association, 2001). The
location of some of these enzymes may prove to be important in the metabolism of
certain medications (National Community Pharmacists Association, 2001). As the
liver is the main organ involved in drug and toxin removal, most CYPs are present
here. A large amount of CYP is however also present in the small intestine. The
multiple forms of cytochrome P450 that exist in liver microsomes have been shown to
play important roles in the oxidation of structurally diverse xenobiotic (foreign drugs
or chemicals) compounds including drugs, toxic chemicals and carcinogens as well as
endobiotic chemicals such as steroids, fatty acids, fat soluble vitamins and
prostaglandins (Fuengerich and Shimada, 1991).
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As this super-family of genes is responsible for metabolising many toxic chemicals
and carcinogens, carrying an allelic variant of any of these genes may affect an
individual's capacity to successfully perform theses tasks (Topic et aI., 2000).
Genetic polymorphism of CYP enzymes has therefore been suggested as a biomarker
. of susceptibility to carcinogens and toxic compounds (Hong and Yang, 1997).
Many of the CYP enzymes are inducible by the compound they metabolise.
Consequently, cytochrome P450s are one of the most extensively studied groups of
proteins, being investigated by researchers in fields as diverse as toxicology,
pharmacology, environmental biology, biochemistry and molecular biology.
Cytochrome P450s are intimately involved with vascular autoregulation in the brain
and are vital to the formation of cholesterol, steroids and arachindonic acid
metabolites.
Regulatory mechanisms for the CYP enzymes vary greatly. Chemical signals can
turn many of these enzymes on or induce their activity. The steroid hormones are
under strict endocrine control and their levels are tightly regulated. One example is
the induction of steroid biosynthetic CYPs by ACTH (adrenocorticotropic hormone).
ACTH stimulates production of 3', 5'-cyclic adenosine monophosphate (cAMP) that
presumably activates a protein kinase that phosphorylates some unidentified protein,
leading to an increase in gene transcription.
Peroxisome proliferators like clofibrate demonstrate another type of CYP gene
regulation. These drugs act through PPAR (perioxisome proliferator activator
receptor), a binding protein which when bound to the drug migrates to the nucleus,
heterodimerises with retinoid X receptor (RXR) and binds to specific DNA sequences
in the regulatory region of genes that are needed for peroxisome generation. In this
way, the CYP4Al gene is turned on. Peroxisomes oxidise fatty acids and CYP4Al is
a known fatty acid hydroxylase.
For data of cytochrome P450 to be accessible and useful, a cytochrome P450
nomenclature system was devised (Nebert et al., 1987). This nomenclature system
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relies on evolutionary relationships as depicted in phylogenetic trees of dendrograms
derived from the CYP protein sequences. The whole collection of sequences
represents the CYP super-family, with families and sub-families being arbitrarily
defined as distinct clusters on the tree. Amino acid sequence similarity is the main
criteria for categorising cytochrome P450 isozymes. CYPs are classified into families
(sharing at least 40% amino acid sequence homology), sub-families (sharing at least
55% amino acid sequence homology) and individual genes. Families are identified by
a number, e.g. CYP3, subfamilies by a letter, e.g. CYP3A and individual genes by
another number e.g. CYP3A4. The number of human CYP genes has been estimated
to 57 and 33 pseudogenes arranged into 18 families and 42 subfamilies (Nebert and
Russell, 2002). The majority of these encode enzymes that function to metabolise
drugs and xenobiotics. The most recent information regarding all the polymorphic
forms of CYPs is found on the Human Cytochrome P450 (CYP) Allele Nomenclature
Committee's web page. Information regarding polymorphic cytochrome P450
nomenclature for all enzyme variants can be found here.
Polymorphic CYP nomenclature is complicated, as presently more than eighty allelic
variants have been described for CYP2D6 alone. The various allelic CYP forms are
found with varying frequencies between various ethnic populations, due to genetic
drift and in some cases genetic selection (Ingelman-Sundberg, 2001). Only CYP1AI
and CYP2E1 seem to show signs of conservation. Distribution of the different CYPs
is remarkably diverse and the high degree of polymorphism observed within these
genes is probably the result of dietary adaptation of the different populations of the
world (Ingelman-Sundberg, 2001). Dietary stress in certain regions therefore resulted
in the accumulation of specific CYP variants in certain populations. Incidental
mutations within the CYP genes are, however, the major cause of the inter-ethnic
differences, which were amplified in certain populations as the populations expanded.
Very little homology between human and rodents is observed for the CYP enzymes
with the exception of CYP1A1 and CYP2El. Rodent models can therefore not be
effectively used for toxicity testing and analysis of drug metabolism (Ingelman-
Sundberg, 1998).
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Consequences of Mutations Within Cytochrome P4S0 genes
Differential cytochrome P450 enzyme activity is observed between individuals and
populations due to genetic variation present in the genes. These inter-individual
differences in enzyme activity may be responsible for serious adverse drug reactions
by a patient when multiple drugs are administered simultaneously. Differential
expression of the cytochrome P450 genes in certain organs may also be held
responsible for the clinical reaction of a patient to a particular drug. Another factor
complicating the prescription of drugs to patients is that cytochrome P450 genes also
seem to show variable expression as individuals age. Neonates lack CYPIA2 and are
therefore highly sensitive to caffeine as CYPIA2 is responsible for the metabolism of
this toxin. The differences in metabolism of drugs due to genetic polymorphism may
lead to different levels of effectiveness of certain drugs. Some genes in the CYP
super-family show polymorphism with varying occurrence of poor and extensive
metabolisers in different populations (Ingelman-Sundberg, 1998). Mutations within
the CYPs can cause the resulting enzyme to have eradicated, reduced, altered or
increased enzyme activity (Ingelman-Sundberg, 2001).
The involvement of cytochrome P450 enzymes in drug interactions has attracted
much attention as knowledge about these enzymes has increased. Certain drugs have
been declared illegal due to the severe reactions that they have with cytochrome P450
enzymes. Each CYP enzyme is affected differently by a drug, a fact that must be
brought into consideration when one is trying to predict or understand CYP-drug
interactions (Evans and Johnson, 2001).
Differences in human cancer susceptibility have been attributed to the occurrence of
polymorphism in the enzymes responsible for metabolising the carcinogens
(MacLeod et aI., 1997, Mucci et aI., 2001). CYPIA2 has been implicated as a risk
factor in urinary bladder (Landi et al., 1996, MacLeod et al., 1997) and colorectal
cancer (MacLeod et al., 1997). MacLeod et al. (1997) suggest that when one is
evaluating the cancer risk for a specific individual, one must take into consideration
the carcinogen exposure and the activities of carcinogen metabolising enzymes
(catalytic products of the enzymes may influence the expression or induction of other
enzymes which either detoxify or activate potentially carcinogenic compounds) of
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that individual. Two genetically linked polymorphisms of CYP1A1, ml (6235 T>C,
MspI polymorphism) and m2 (4889 A>G, Ile-Val substitution) are associated with
increased breast cancer risk (Huang et al., 1999). A single T to C substitution
polymorphism within the CYP17 5' promoter-region has been described by Carey et
aI., 1994. The T-allele has been referred to as the Al allele and the C-allele as the A2
allele. Data from Feigelson et al. (1997) found an increased risk of advanced breast
cancer in women who carry a single A2 allele of CYP 17 and Spurdle et al. (2000)
suggest that the CYP17 A2A2 genotype may be implicated in early-onset familial
breast cancer. Kristensen and Berresen-Dale (2000) suggest that individuals carrying
the long allele of CYP19 are also at an increased risk of developing breast cancer.
Imaoka et al. (2001) suggests that the possibility exists that gender-specific
expression of CYP4B 1 in bladder tissue may contribute to male-dominant expression
of bladder carcinoma.
Complete inactivation of CYP3A4 is thought to be incompatible with life, which may
explain why no completely inactivating mutations have been found within the gene
(Evans and Johnson, 2001).
Gene Duplications and Clinical Effects of Gene Duplication
Ultra rapid metaboliser phenotype is the result of duplicated or multi-duplicated
copies of a gene encoding a drug metabolising enzyme. Table 2.01 summarises the
clinical importance of the ultra rapid metaboliser phenotype in drug metabolism. It is
crucial to identify patients with this phenotype before drug treatment commences to
allow for optimal treatment.
Multiple copies of a functional CYP2D6 gene have been observed in Ethiopian and
Saudi Arabian populations at high frequencies, 29% and 20% respectively (Ingelman-
Sundberg, 1998). Duplications of this gene are observed in much lower frequencies
in other populations e.g. in Swedes, Zimbabweans and Chinese, multi-duplication
occurred at a frequency of only 2% (Ingleman-Sundberg, 1998). The belief therefore
exists that dietary selection pressure existed in Saudi Arabia and Ethiopia that
favoured the preservation of alleles consisting of duplicated or multi-duplicated
genes, and these were introduced to other counties during the Muslim migration. In
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support of this hypothesis, it has been observed that very few defective CYP2D6
alleles have been reported in Ethiopian and Saudi Arabian populations.
A consequence of this gene multi-duplication effect is that a drug fails to deliver any
therapeutic effect at standard doses in patients carrying more than three functional
CYP2D6 genes. Evidence in support of this has been demonstrated by Dalén et al.
(1998). Dalén and his co-workers showed that plasma levels of nortriptyline are
reduced in a proportional manner to the number of gene copies harboured by the
individual. The number of primary metabolites are however also proportional to the
number of active genes. If this goes undetected in patients, it may result in dire
consequences during therapy with drugs whose primary metabolite is toxic or
addictive e.g. codeine whose primary metabolite is morphine. Morphine addiction
may be induced in patients carrying three or more functional CYP2D6 genes
(Ingelman-Sundberg, 1998).
2.2.2.1.2 Other Phase I Enzymes
Other phase I drug metabolising enzymes include the five flavin-containing
monooxygenase (FMO) isoforms (FMOI - FM05). They comprise a membrane-
associated, widely distributed family of enzymes that catalyse the oxidation of
nucleophilic nitrogen-, sulfur- and phosphorous-containing xenobiotics, drugs and
endogenous substances (Zeigler, 1993). The role of FMOs in human metabolism as
suggested by Ziegler (1993), is to metabolise xenobiotics from plant sources to
materials that are not pharmacologically or toxicologically threatening to the
organism ingesting the chemical. Zhang et al. (1995), Cashman et al. (1997), Dolphin
et al. (1997) and Treacy et al. (1998) have described mutations of the human FM03
gene that cause trimethylaminuria, an inborn error causing a deficiency in N-
oxygenation of the odorous tertiary amine TMA (tertiary amine trimethylamine) to its
non-odorous metabolite TMAN-oxide.
2.2.2.2 Phase II Enzymes
Phase II enzymes comprise at least four classes, a, m, p and q (Murata et al., 1998)
and are characterised by their diverse substrate specificity and polymorphism (Board
et al., 1998).
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N-acetyltransferase (NATs) enzymes show genetic polymorphism that influences
their capacity to deactivate aromatic amines and other environmental exposures, and
activation of heterocyclic amines produced during the cooking of meats. They
catalyse generally considered detoxifying reactions (N-acetylation) or intermediate
reactions leading to DNA reactive intermediates (O-acetylation of N-
hydroxyarylamines stemming from previous CYP metabolism) (Weber and Vatsis,
1993). Two N-acetyltransferase genes have been identified, NAT-l and NAT-2, along
with one pseudogene NATP. N-acetylation polymorphism was identified late in the
1940swhere researchers phenotyped individuals as slow or rapid acetylators. NAT-2
has been identified as the gene principally involved with slow and rapid acetylator
phenotype. Three major slow-acetylator alleles have been independently identified in
many human populations (Nebert and Roe, 2001). Two of them are common in
Caucasians and one in Asians. Slow acetylator phenotype has a high incidence in
bladder cancer (Gonzalez and Idle, 1994).
Uridine diphosphate glucuronosyltransferase (UDPGT) enzymes show considerable
diversity generated by multiple copies of exon one being alternately spiced with exons
two to five (Board et al., 1998). A TA insertion in the UGTIAI promoter region
reduces the expression of this enzyme and is subsequently the cause of Gilbert's
syndrome (Innocenti and Ratain, 2002).
Glutathione S-transferases (GSTs) compnse a family of multifunctional dimeric
proteins that catalyse glucuronide formation using many endobiotic and xenobiotic
compounds as substrates. Their primary function is to detoxify electrophiles capable
of binding to DNA (Taningher et al., 1999). Determining and predicting GSTs
specificity remains a challenge for researchers. Four classes of human cytosolic
GSTs have been distinguished: a (GSTA), ~ (GSTM), 1t (GSTP) and e (GSTT)
(Mannervik et al., 1992). Increased cancer susceptibility due to deficient
detoxification has been associated to a deletion of the GSTMI gene (Taningher et al.,
1999). GSTP 1 polymorphism has also been implicated with other cancer
susceptibilities (Harries et al., 1997).
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TPMT (thiopurine methyltransferase) is a polymorphic phase II enzyme responsible
for catalysing the S-methyltransferase of thiopurine medications (e.g. 6-
mercaptopurine in chemotherapy), the inactivation pathway in hematopoietic tissues.
Patients homozygous for the non-functional TPMF allele, develop dose-limiting
hemapoietic toxicity that may result in death if the patient receives full doses of
thiopurine medications. Treatment with 5-10% of the conventional dose results in
successful treatment with only acute toxicity. Individuals heterozygous at the TPMF
locus have a greater risk of thiopurine toxicity than those homozygous for the normal
allele. Dosage has to be moderately reduced for these patients (Evans and Johnson,
2001).
2.2.3 Drug Receptors
Evans and Johnson (2001) define a drug target as "the direct protein target of a drug
(e.g. a receptor or an enzyme), proteins involved in the pharmacologic response (e.g.,
signal transduction proteins or downstream proteins), or proteins associated with
disease risk or pathogenesis that is altered by the drug." Generally two types of
receptors are recognised based on location and mechanistic features, those present in
the cytoplasm and those that insert into and traverse cell membranes. Selectivity and
specificity of drug action is a function of the selective localisation of the drug
receptors, the specificity of the drugs that bind to the particular receptor, the strength
of the drugs' attachment to the receptor and the consequences of interaction between
the drugs and the receptors. Receptors display varied levels of sensitivity depending
on the individual's age, genetic factors, drug interactions and disease states.
Pharmacogenetics of drug receptors is a very new field of research that only came into
being in the 1990's. Many of the researchers in this field have investigated the
contribution single polymorphisms or single genes have on the expected response to a
medication, and they have been successful in finding associations between certain
polymorphisms and the drug response. The results of these studies have, however,
been documented very inconsistently. The angiotensin converting enzyme (ACE)
gene is a very popular drug target in many of these studies. Studies of an
insertion/deletion (IID) within the gene have yielded contradictory results, in that
some studies show no association between response and ACE lID genotype (Cannella
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et al., 1998), others report association of the VI genotype to greater drug response
(Kohno et al., 1999) and others report association of the DID genotype with greater
drug response (Hernandez et al., 2000).
Other genes coding for drug receptors that have received much attention include the
~2-adrenergic receptor gene, dopamine receptor genes and the serotonin (5HT)
receptor genes. Many mutations within the androgen receptor have been found
associated with prostate cancer (Scher and Kelly, 1993, Schoenberg et al., 1994).
2.2.4 Use of Pharmacogenomics Today and Implications for the Future
The ability to provide every individual patient with an individualised drug efficacy
and safety likelihood profile will change the practice and economics of medicine. The
test in itself will have great economic significance. Streamlined drug development
and the concurrent development of discrete medicines for patients with similar disease
phenotypes will result from the ability to rapidly profile patients who seem likely to
benefit from a particular medication. Pharmacogenetic profiles will soon be
developed which will enable one to determine the likelihood of an individual
responding to the medication and/or the likelihood of an individual expenencmg
adverse side effects from the medication (Roses, 2000).
The application of pharmacogenomics to the delivery of medicines will maximize the
value of each medication. Pharmacogenomics has the potential to impact medical
care at many different levels. As medications that treat, cure or prevent common
diseases become a more significant part of medical care, the costs of debilitating
illnesses will be drastically reduced. A great sum of money will be saved once the
practice of treatment and prevention of chronic and common disease improves by
simply resulting in a reduction in the length of a hospital stay and long-term care
costs. These savings could then be transferred to well-tolerated and effective
medicines. Prevention of drug-caused morbidity and mortality should be possible
through the successful application of pharmacogenomic research (Nebert, 1999).
Evans and Johnson (2001) suggest that if drug receptor pharmacogenomics is to be
used as a reliable tool in the prediction of drug response and for making suitable
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therapeutic decisions based on this information, more sophisticated genomic
approaches will have to be implemented. This will involve approaches such as the
"candidate gene" pharmacogenetic approach, where the polymorphisms in many
genes suspected or known to contribute to drug effects or disposition are studied to
gain insight of their association with drug response or toxicity. Drysdale et al. (2000)
have shown that haplotype analysis considerably enhances ones ability to detect
important associations between gene polymorphisms and drug response.
The future ofpharmacogenomics' acceptance as common practice will rely heavily on
its ability to provide results that can be easily understood by persons with a general
medical background, and not only molecular biologists. For pharmacogenomics to be
widely applied the tests will have to be simplified as much. as is allowed, and the tools
allowing interpretation of the results will have to be made available in a user friendly
manner. Testing technologies and test validation are the two factors that will affect
the availability of pharmacogenomic testing as a part of routine drug selection (Spear
et al., 2001).
A consequence of pharmacogenomic testing that will have to be addressed is that of
genetic counselling, prior to and after a patient has undergone such a test. Topics
such as what the test can/can not reveal, the availability of treatment options and the
meaning of the test results will have to be discussed at length with the patients.
Simultaneous testing for multiple genetic markers of different conditions will
complicate issues even further as how does a counsellor prepare an individual for
results that indicate that the patient has the genetic markers associated with
susceptibility for a number of genetic diseases or disorders? It is valid to therefore
say that the volume of information resulting from pharmacogenomic tests may prove
to be overwhelming to both the patients and the medical professionals.
2.3 PATIENT GROUPS
Variegate porphyria and breast cancer are two diseases that have great clinical
relevance in the South African population due to the high observed prevalence of the
diseases. The focus of future studies involving these patients will include determining
variation in drug response, but before this can become a reality, a need exists to
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identify the relevant polymorphisms In as many South African populations as
possible.
2.3.1 Variegate Porphyria (VP)
With the exception of erythrocytes, all tissues exhibit aerobic metabolism and
therefore require mitochondrial cytochromes. Functional cytochrome P450 enzyme
production requires the incorporation of haem to the apoprotein. All cells should
therefore produce enough haem to meet the need for cytochrome production. In the
liver fifty percent of synthesised haem is used in the formation of CYP. Synthesis of
cytochrome P450 accounts for the high rate of haem synthesis in the liver and changes
in the production of CYP would surely cause major changes in the rate of hepatic
haem synthesis. The induction of CYPs by a substrate (drug or lipophilic endogenous
substance) will lead to the removal or activation of that particular substance, a
reaction that requires synthesis of new CYP, which in turn requires the synthesis of
new haem. Haem regulates the amount and the activity of CYP proteins in three ways
(De Matties and Marks, 1996). These are listed in Table 2.04. In persons suffering
from conditions collectively known as porphyrias, this could be problematic as the
flow of intermediates within the haem biosynthetic pathway may be partially or
totally blocked, limiting the capacity for increased haem biosynthesis.
Table 2.04: Regulatory mechanisms of CVP protein quantity and activity by
haem.
• Incorporation of haem to the apoprotein of CYP is essential to ensure the assembly
of functional holoprotein
• Haem-exchange allows a haem deficient CYP to require at least part of its original
haem compliment
• Inhibition of haem biosynthesis in rats inhibits induction of CYPs
(De Matties and Marks, 1996)
The porphyrias are a heterogeneous group of inherited disorders of haem biosynthesis.
All living organisms produce porphyrins, porphyria patients simply accumulate
porphyrins in an atypical manner. Haem biosynthesis converts two simple substrates,
ê-aminolevulinic acid (ALA) and porphobilinogen (PBG) (porphyrin precursors) into
25
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO
identify the relevant polymorphisms m as many South African populations as
possible.
2.3.1 Variegate Porphyria (VP)
With the exception of erythrocytes, all tissues exhibit aerobic metabolism and
therefore require mitochondrial cytochromes. Functional cytochrome P450 enzyme
production requires the incorporation of haem to the apoprotein. All cells should
therefore produce enough haem to meet the need for cytochrome production. In the
liver fifty percent of synthesised haem is used in the formation of CYP. Synthesis of
cytochrome P450 accounts for the high rate of haem synthesis in the liver and changes
in the production of CYP would surely cause major changes in the rate of hepatic
haem synthesis. The induction of CYPs by a substrate (drug or lipophilic endogenous
substance) will lead to the removal or activation of that particular substance, a
reaction that requires synthesis of new CYP, which in turn requires the synthesis of
new haem. Haem regulates the amount and the activity of CYP proteins in three ways
(De Matties and Marks, 1996). These are listed in Table 2.04. In persons suffering
from conditions collectively known as porphyrias, this could be problematic as the
flow of intermediates within the haem biosynthetic pathway may be partially or
totally blocked, limiting the capacity for increased haem biosynthesis.
Table 2.04: Regulatory mechanisms of CVP protein quantity and activity by
haem.
• Incorporation of haem to the apoprotein of CYP is essential to ensure the assembly
of functional holoprotein
• Haem-exchange allows a haem deficient CYP to require at least part of its original
haem compliment
• Inhibition of haem biosynthesis in rats inhibits induction ofCYPs
(De Mattles and Marks, 1996)
The porphyrias are a heterogeneous group of inherited disorders of haem biosynthesis.
All living organisms produce porphyrins, porphyria patients simply accumulate
porphyrins in an atypical manner. Haem biosynthesis converts two simple substrates,
ê-aminolevulinic acid (ALA) and porphobilinogen (PBG) (porphyrin precursors) into
25
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO
more complex porphyrins. Porphyrins are converted from one type to another until
protoporphyrin is complexed with iron to eventually form haem. Each step of this
pathway is catalysed by a specific enzyme. As free porphyrins are produced only in
minute quantities in humans as the accidental side products of haem biosynthesis, the
presence of increased porphyrins in urine or faeces is an indication of a disturbance
within the haem-biosynthesis pathway.
Variegate porphyria (OMIM #176200) is an autosomal dominant disease with
variable clinical expression and a low penetrance, with some carriers being
asymptomatic. VP is classified as an acute hepatic porphyria and a toxico-genetic
disease (genetically acquired disease showing idiosyncratic reaction to drugs). VP
patients and asymptomatic carriers have a 50% reduction in the activity of
protoporphyrinogen oxidase which catalyses the conversion of protoporphyrinogen IX
to protoporphyrin IX in mitochondria (Deybach et al., 1981 and 1985).
Numerous mutations within the protoporphyrinogen oxidase gene (PPOX) have been
identified (Whatley et aI., 1999, Human Gene Mutation Database, 2002) and support
the conclusion that defects within the PPOX gene cause variegate porphyria.
Variegate porphyria has an unusually high incidence in South Africa. Genealogical
and molecular genetic studies of South African variegate porphyria families have
demonstrated that this is the result of a founder gene effect caused by the introduction
ofa single mutation, R59W, by one of two Dutch immigrants in 1688 (Dean, 1971,
Meissner et al., 1996,Warnich et al., 1996, Groenewald et al., 1998). The frequency
of this mutation was estimated to be 0.003 in the Caucasian Afrikaans population
(Dean, 1971), and is present in approximately 94% of South African VP subjects
(Meissner et al., 1996).
Clinical manifestations of the disease include cutaneous photosensitivity and acute
neurovisceral crises that may occur separately or in combination (Kirsch et al., 1998).
Cutaneous photosensitivity is the result of the circulating porphyrins. Excessive
fragility of skin is observed in patients, especially in sun-exposed areas. The skin
lesions consist of a bullous eruption leading to ulceration and chronic scarring usually
involving the extensor surface of the hands and the face. Damaged areas of the skin
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frequently take long to heal properly. The skin of porphyria sufferers often becomes
thin, dark and scarred and sometimes rather hairy, particularly on the face. The
primary site of skin damage is in the vessel wall (Timonen et al., 1990).
Acute attacks rarely occur before puberty and are most common during the second to
forth decades of life (Elder et al., 1997). They occur more frequently among women
than men and vary in their clinical presentation. The most common symptom is
abdominal pain that may be severe and continuous, and may affect any part of the
abdomen, spreading to the back, buttocks and thighs (Elder, 1997). Large amounts of
opioids may be required to control the pain. Dehydration is common and
inappropriate secretion of vasopressin results in hyponatraemia. Sodium levels
frequently drop to levels that result in the occurrence of convulsions. Acute attacks
may progress to a neuropathy, affecting mainly the motor nerves but mild disruptions
in sensory nerves have been described and include hypoaesthesia. Tachycardia,
hypertension, vomiting and constipation may all occur, due possibly to autonomic
neuropathy (Gordon, 1999, Medlock et al., 2002). After repeated attacks, wrist and
foot dropping may develop. Widespread muscle weakness, dysaesthesia and
causalgia may also occur and cranial palsies have been recorded. Other features
include abnormal behaviour, confusion, agitation, anxiety and hallucinations. Urinary
abnormalities are frequently observed during an attack as an increased excretion of
porphyrin precursors ALA and PBG giving rise to red winelbrown coloured urine. In
the faeces, increased excretion of protoporphyrinogen and coproporphyrinogen has
been observed (Dean, 1971, Mustajoki, 1978, Meyer and Schmid, 1978, Da Silva et
al., 1995). Neurological symptoms are also apparent during the attack and range from
headaches to paralysis. Abdominal tenderness and diminished bowel sounds are also
commonly observed. If death follows an attack it is usually due to respiratory failure
and complications due to incorrect management of the respiratory problems.
Variation of genetic characteristics may explain the observed variance in disease
manifestation. Commonly used drugs can precipitate an illness, by increasing the
synthesis of cytochrome P450 enzymes in the liver that result in an increased
synthesis of haem. Known inducers of the symptoms of acute intermittent porphyria
(AlP) include sedatives, sulfonamides, erthromycin, griseofulvin, estrogenic
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hormones and anti-seizure medications, all of which are metabolised by the enzyme
products of CYP genes. Inability, due to CYP polymorphism, to successfully
metabolise these drugs may result in a patient developing symptoms of AlP.
Barbiturates are absolutely contraindicated in AlP (American Academy of
Anaesthesiologist Assistants, 2001). Porphyria cutanea tarda (PCT) is induced in
adults due to exposure to environmental toxins including dioxin containing
herbicides, cyclic (polychlorinated) hydrocarbons, alcohol and oestrogens. These
substances may be inducers of PCT due to the inability of the specific CYP to
successfully metabolise these compounds (American Academy of Anaesthesiologist
Assistants, 2001). Porphyria patients are strongly recommended to avoid many
commonly prescribed medications due to the many negative side effects experienced
after their administration. Drugs that can precipitate an acute attack have a common
characteristic - the ability to increase the activity of ê-aminolevulinic acid synthase,
the rate limiting enzyme of the haem biosynthesis pathway (Gordon, 1999). Other
factors precipitating acute attacks include fasting, menstruation, pregnancy, stress,
alcohol and infections (Kauppinen and Mustajoki, 1992, Zimmerman et al., 1996,
Elder et al., 1997). Menstruation and pregnancy may precipitate acute attacks due to
the fact that hormonal changes are experienced and gonadal steroids are metabolised
in part by CYPs and may therefore endogeneously increase the rate of haem
biosynthesis in women.
Acute attacks may be successfully managed by paying particular attention to the
medication the individual is receiving. Many patients in South Africa are however,
apparently unaware of their positive porphyria status, and are therefore at an increased
risk for experiencing acute attacks (Jenkins, 1996).
2.3.2 Breast Cancer
Cancer is the result of a loss of balanced gene expression caused by a process of
mutation in key regulatory genes and epigenetic alterations (Danesi et aI., 2001). It
results in the excessive proliferation of cells due to the cells' ability to divide without
stimulation from other cells and their unresponsiveness to the normal controls of cell
proliferation. Cancer cannot be considered purely genetic or purely environmental
(Hoover, 2000, Lichtenstein et al., 2000). Research is now focusing on alterations in
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DNA that are more common, but that on their own may not significantly impact
disease risk. However, together with environmental exposures, these genetic
alterations may lead to the development of cancer, so called co-participation (Mucci
et al., 2001).
Breast cancer is one of the most common causes of death in women and the most
frequently diagnosed cancer in women from all ethnic groups (Greenlee et al., 2001,
Jemal et al., 2002). More South African women die annually from breast cancer than
any other cancer including cervical cancer which previously was the leading cause of
cancer related deaths (SAPA, 10110/2002). Epidemiological studies indicate that the
age of onset is steadily, albeit slowly, decreasing. This is indicative of the role
changing environmental factors have on the development of breast cancer.
Last century, BRCAl, BRCA2 and p53 were identified and declared as the
susceptibility genes for breast cancer (Williams and Anderson, 1984, Hall et al., 1990,
Wooster et al., 1994). Investigators now conclude that there are as many as four to
twelve major genes and many other modifier genes responsible for increased breast
cancer risk (Nebert, 1999). It has been postulated that the possibility exists that "low-
risk" genetic factors, that are more common than the "high-risk" mutations in BRCAI
and BRCA2, explain the familial aggregation of breast cancer (Spurdle et aI., 2000).
Modifying factors for increased breast cancer risk or toxicity to drugs and
environmental agents clearly include many drug metabolising enzymes, drug
receptors, and drug transport genes (Nebert and Roe, 2001). Many of the genes
encoding carcinogen metabolising enzymes are polymorphic (Mucci et al., 2001).
Some of these variants result in changes in the enzyme, while others increase or
decrease the rate at which metabolism of the substrate occurs, and others alter the
expression of the enzyme. Susceptibility to cancer may be influenced by altered
exposure of cells to the carcinogens, or may be due to the genetic variations within the
genes encoding the metabolising enzymes (Mucci et aI., 2001). The last 25 years of
research have resulted in the identification of many risk and protective factors for
breast cancer, all of which culminate in the exposure of breast tissue to oestrogen and
perhaps progesterone (Feigelson and Henderson, 1996). The existence of
susceptibility genes carrying "low absolute risk" and potentially "high population-
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attributable risk", especially when considered in combination, has been hypothesised
(Feigelson et al., 1997).
Oxygenated metabolites of oestrogen have newly generated hydroxyl and keto
functions, which markedly affect their biological activities (Martucci and Fishman,
1993). Independent studies by Yager et al. (1996), Cavalieri et al. (1997), and Zhu
and Conney (1998) have shown that oestrogen metabolites can bind to DNA,
triggering damage. These results have lead to Service (1998) suggesting that
oestrogen may be a complete carcinogen that can directly cause genetic alteration and
effect tumour initiation. Catechol oestrogen (CE), a metabolite of oestrogen, has been
proposed as the initiating mechanism triggering breast cancer (Huang et al., 1999) and
has been shown to be carcinogenic in animal models (Shimada et al., 1996).
Cytochrome P450 enzymes are involved with CE formation via oestrogen
biosynthesis (CYPI7) and hydroxylation (CYPIA1). Extrahepatic tissues such as
breast tissue rely on CYPIBI for the homeostasis of oestrogen. Furthermore,
CYPIBI and CYPIAI have been shown to catalyse the formation of mutagenic
intermediates from many polycyclic aromatic hydrocarbons, including many that are
potent mammary gland carcinogens in rodents (Bailey et al., 1998). Drugs and
foreign chemicals with structural similarity to endogenous ligands that playa role in
the regulation of oestrogen metabolism can alter the level of the various oestrogen
metabolites. Additional CYPs are responsible for restoring the balance of oestrogen
hormone action, hereby neutralising the disturbance (Martucci and Fishman, 1993).
Formation of reactive species leading to an increased degree of carcinogenesis has
been proposed to be the price paid for tight regulation of steroid hormones (Nebert,
1991).
Interindividual variance in therapeutic drug response and drug toxicities is a cause of
great concern for clinicians. This variance results from polymorphism in genes
coding for drug metabolising enzymes or drug receptors. Therapeutic agents'
pharmacokinetics are altered as a result of polymorphism in drug metabolising
enzymes (lyer and Ratain, 1998). Innocenti et al. (2002) is of the opinion that
genotypic stratification of patients might identify subgroups with an enhanced
prognostic profile to chemotherapy response and survival. Selection of alternative
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therapies may be guided by the presence of alleles associated with reduced
responsiveness to certain drugs. The unpredictability of cancer treatment will be
reduced by the identification of genetic reasons explaining the occurrence of toxicity
or lack of tumour response to treatment.
A great challenge in cancer research is to identify, in precise detail, the series of
abnormalities that arise in the genomes of all types of cancer, to use the newly
identified information to understand malignancy and ultimately to develop more
rational and effective strategies for diagnosis and treatment of cancer. The use of
chemotherapy as a treatment for cancer is limited due to the fact that the choice of
treatment protocol is still empirical and makes no account of tumour biology. Data
exists that shows that patients with seemingly identical tumours may respond
differently to treatment. Pharmacogenomics now seeks to answer many questions
regarding the success of chemotherapy in some cancers and the unsuccessful results in
others, as the influence that genetics has on the response to anti-cancer agents is yet to
be determined and understood fully. Pharmacogenomics will aid in the determination
of the roles played by gene products (enzymes) in either directly or indirectly
influencing the activity of chemotherapeutic agents. Decreases or increases in the
normal activities of these enzymes are associated with drug resistance, therefore the
expression of the target enzyme in the tumour must be taken into consideration in
order to maximize the chances of therapeutic success (Danesi, 2001). Creation of
individualised chemosensitivity-chemoresistance maps would help III the
identification of drug combinations for optimal treatment. Creation of these maps
will only be possible once the genes responsible for sensitivity to drugs have been
identified and the patients have been screened.
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2.4 AIMS OF THE STUDY
The general aim of this study was to investigate whether an association exists between
various cytochrome P450 polymorphisms and two disease groups.
Specific Aims of the Study
Variegate Porphyria Study (Addressed in Chapter Three)
Identification of "unsafe" drugs for porphyria patients and the cytochrome
P450s responsible for their metabolism from literature;
11 Selection of polymorphisms within a number of relevant cytochrome P450
genes and subsequent molecular screening of the patient and control groups
for the selected polymorphisms;
111 Statistical analysis and evaluation of the results generated to determine
whether an association exists between any or all of the polymorphisms and
variegate porphyria (disease group and various symptoms).
Breast Cancer Study (Addressed in Chapter Four)
Selection of polymorphisms within the relevant cytochrome P450 genes and
subsequent molecular screening of the patient and control groups for the
selected polymorphisms;
11 Statistical analysis and evaluation of the results generated to determine
whether an association exists between any or all of the polymorphisms and
increased risk of developing breast cancer in two South African population
groups (Caucasian and of mixed ancestry).
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CHAPTER THREE
CYP POLYMORPHISMS IN SOUTH
AFRICAN VARIEGATE PORPHYRIA
PATIENTS: AN ASSOCIATION STUDY
3.1 ABSTRACT
Variegate porphyria (VP), an autosomal dominant disease with low penetrance, is a
disorder of haem biosynthesis. The R59W mutation within the PPOX gene
(protoporphyrinogen oxidase, the seventh enzyme in the haem biosynthesis pathway)
is associated with a founder gene effect among the South African VP population.
Clinical expression of the disease varies, but is characterised by neurovisceral attacks
and skin lesions, alone or in combination. Some patients are asymptomatic. It is
expected that modifier loci and environmental factors are important contributors to
the varied clinical expression observed. Neurovisceral attacks may be precipitated by
the administration of certain drugs introducing a role for drug metabolising enzymes
as possible modifier genes. It is thought that the induction of cytochrome P450
(CYP) enzymes (phase I drug metabolising enzymes) by drugs results in an increased
demand for hepatic haem, leading to the induction of haem biosynthesis.
Accumulation of excess metabolites in VP patients prior to the enzymatic block may
limit the capacity for increased haem synthesis, hereby reducing the expression of
functional CYP, leading to incomplete drug metabolism. A clinically characterised
VP disease group consisting of four clinical subgroups (asymptomatic, acute attacks,
skin lesions, acute attacks and skin lesions) and a healthy control group were included
in this study. Six CYP polymorphisms (CYPIAlml, CYPIAlm2, CYPIA2 -734
C>A, CYPIBI 8372 A>C, CYP2D6*3 and CYP2D6*4), associated with four CYP
loci, were genotyped in these groups. Significant differences in CYP1B1 genotype
distributions (P<O.OOI) and allele frequencies (P<O.0004) were observed after
Bonferroni correction for the VP disease group, the skin lesion clinical subgroup, the
total acute attacks group and the total skin lesion group versus the control group.
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Prior to Bonferroni correction, significant differences in CYP1B1 genotype
distributions (P<0.03) and allele frequencies (P<0.025) were observed for
comparisons between the acute attacks clinical subgroup versus the controls and for
the total acute attack and the total skin lesion group versus the asymptomatic clinical
subgroup. CYP1A1ml genotype distributions (P<0.04) and allele frequencies
(P<0.05) yielded significant differences prior to Bonferroni correction for the skin
lesion and the acute attack and skin lesion clinical subgroups versus the acute attacks
clinical subgroup. The A-allele of CYP1B1 demonstrated an allele frequency of
100.00% for all the clinical subgroups presenting with acute attacks. Although the
numbers of patients included in this study are relatively small, the results observed in
the CYP1B1 analysis indicate a possible role for CYP1B1 in the modification of the
clinical expression of VP in South Africa.
3.2 INTRODUCTION
Variegate porphyria (OMIM #176200), an autosomal dominant disease with low
penetrance, is a disorder of haem biosynthesis. Heterozygous individuals have a 50
percent reduction in the activity of the seventh enzyme in the haem biosynthesis
pathway, protoporphyrinogen oxidase (PPOX). PPOX catalyses the conversion of
protoprophyrinogen IX to protoporphyrin IX in mitochondria (Deybach et al., 1981
and 1985). The reduced activity of PPOX in VP patients results in the accumulation
of porphyrins and increased porphyrin levels are observed in stool and urine samples
of affected individuals, especially during and just after a neurovisceral attack (Dean,
1971, Mustajoki, 1978, Meyer and Schmid, 1978, Da Silva et aI., 1995). Clinical
expression of the disease varies but is characterised by neurovisceral attacks and skin
lesions alone or in combination. Some patients are however asymptomatic. Acute
attacks occur more frequently among women than men and vary in their clinical
presentation. Menstruation and pregnancy may precipitate neurovisceral attacks due
to the fact that hormonal changes are experienced and gonadal steroids are
metabolised in part by CYPs and may therefore endogenously increase the rate of
haem biosynthesis in women. The mechanism giving rise to the varied symptoms is
as yet unknown but it is expected that modifier loci and environmental factors are
important in this regard (Elder, 1998, Warnich et al., 2002). The unique founder
population of South Africa (Dean, 1971, Meissner et al., 1996, Warnich et aI., 1996,
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Groenewald et al., 1998) with numerous individuals all having the same mutation
(R59W in PPOX), provides a unique opportunity to identify genes that may be
responsible for modifying the clinical expression ofVP.
The administration of certain drugs is known to precipitate neurovisceral attacks
therefore great caution should be exercised when prescribing medication to a
porphyria patient (SAMF, 2000). Genetic variations in drug metabolising enzymes
are therefore implicated as candidate loci responsible for modifying the clinical
expression of VP. Fifty percent of the haem produced in the liver is used as a
component of cytochrome P450 enzymes, the most important drug metabolising
enzymes in humans (Guengerich et al., 1998, Graham and Peterson, 1999, lngelman-
Sundberg, 2001). Drug induced porphyrinogenicity is complex, but it is thought that
the induction of CYPs by drugs results in an increased demand for hepatic haem,
leading to the induction of haem biosynthesis (Hindmarsh, 1993), and the subsequent
accumulation of excess metabolites prior to the enzymatic block. This limits the
capacity for increased haem synthesis, which subsequently reduces the expression of
functional CYP and leads to the incomplete metabolism of the drug concerned.
Genetic polymorphism of the CYP genes may result in an individual being
particularly sensitive to a specific drug. An example of drug sensitivity is shown in
known inducers of the symptoms of acute intermittent porphyria (AlP), which include
sedatives, sulfonamides, erthromycin, griseofulvin, estrogenic hormones and anti-
seizure medications, all of which are metabolised by the enzyme products of CYP
genes. Inability due to CYP polymorphism, to successfully metabolise these drugs
may result in a patient developing symptoms of AlP. Barbiturates are absolutely
contraindicated in AlP (American Academy of Anaesthesiologist Assistants, 2001).
Porphyria cutanea tarda (PCT) is induced in adults due to exposure to environmental
toxins including dioxin containing herbicides, cyclic (polychlorinated) hydrocarbons,
alcohol and estrogens. These substances may be inducers of PCT due to the inability
of the specific CYP to successfully metabolise these compounds (American Academy
of Anaesthesiologist Assistants, 2001).
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Christiansen et al. (2000) suggest that the CYPIA2 AlA genotype is associated with
predisposition to development of clinically manifest porphyria cutanea tarda (PCT).
PCT is characterised by decreased activity of uroporphyrinogen decarboxylase
(UROD) (Kappas et aI., 1995, Elder, 1998) and the subsequent development of
photosensitisation of skin due to the accumulation of uroporphyringen and other
substrates of the UROD reaction (Bickers and Pathak, 1993). A 75% decrease in
UROD activity is necessary before porphyrin formation is increased to levels that
cause photosensitisation (Elder, 1990). The rate of inactivation of hepatic UROD in
PCT and experimental uroporphyrias is influenced by three main factors: iron, the
CYPIA subfamily and ê-aminolevulinic acid (ALA) (Elder and Roberts, 1994).
Approximately 25% of VP patients demonstrate reduced UROD activity (Day et al.,
1982, Day 1986). Elder (1990) has suggested a model explaining this: an oxidative
reaction catalysed by a CVP (for example CYPIA2) converts uroporphyrinogen to the
non-metabolisable uroporphyrin and/or a CVP catalysed oxidative reaction generates
a liver specific UROD inhibitor. Smith and Francis (1987) isolated a UROD inhibitor
from livers of rodents with uroporphyria. A hypothetical explanation for an
association between increased CVP activity and VP therefore lies in the formation of
a similar UROD inhibitor for humans. UROD activity seems to be less inhibited
without iron loading in a 3-week rat model of PCT (Franklin et al., 1998) while
porphyrin accumulation is dramatically reduced under the same conditions.
In this case-control association study, we evaluate the contribution of polymorphisms
in CYPIA1, CYPIA2, CYPIB1, and CYP2D6 to a well defined clinical endpoint in
South African variegate porphyria (disease group and subgroups) patients and a
relevant control group. These four genes were chosen due to the important role they
have in metabolising drugs contraindicated in porphyria patients (CYP2D6), the role
they have in metabolising environmental pollutants and toxins (CYPIAI and
CYPIBI) and due to demonstrated association with clinical expression of other types
of porphyria (CYPIA2).
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3.3 MATERIAL AND METHODS
3.3.1 Study Populations
Blood samples from 30 VP patients were collected and were genetically diagnosed as
being R59W heterozygotes. Extensive clinical evaluation of the patients at Tygerberg
Hospital resulted in the patients being subdivided into four clinical subgroups: acute
attacks, skin lesions, acute attacks in combination with skin lesions and asymptomatic
(Steyn, 2002). A baseline questionnaire collected information on potential risk
factors for VP as well as lifestyle habits. The patients had a mean age of 44 years and
ranged in age from 11 years to 71 years. Individuals constituting the healthy control
population (n=83) were randomly selected. The same control group was genotyped
for each polymorphism. All individuals participating in this study gave their written
informed consent. Ethical approval was given by the Ethical Committee of the
Faculty of Health Sciences, University of Stellenbosch.
3.3.2 DNA Extraction
Total genomic DNA was extracted from whole blood using a modified protocol of
Miller et al. (1998) (refer to Appendix A for a detailed protocol) and the extracted
DNAwas stored at -20°C until genotype analysis.
3.3.3 Selection of CVP polymorphisms
Alphabetical lists of drugs and guidelines for their use by porphyria patients were
downloaded from the University of Cape Town's liver clinic (2001) and the
University of Queensland's porphyria guide (2001) webpages. Lists of drugs unsafe
for use by porphyria patients were compiled using the downloaded lists, SAMF
(2000) and MIMS (2001). The CYPs involved in the metabolism of these unsafe
drugs were identified using information from Gentest (2001). CYPs important in the
metabolism of many of the unsafe drugs were selected and polymorphisms within
these genes were identified from literature.
3.3.4 Genotyping of Cytochrome P450 Polymorphisms
PCR-based RFLP assays were used to determine the CYPIAlml, CYPIAlm2,
CYPIA2 and CYP2D6*4 genotypes (see Appendix B for a detailed protocol).
Genotyping of the CYPIBI polymorphism was performed using the polymerase chain
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reaction heteroduplex single strand conformation (PCR-hex SSCP) (Kotze et al.,
1995) method of detection. The primers were designed from the CYP1B1 sequence
(gi 17446619,NCBI) using the program Primer3 available online (Table 3.01). PCR
was employed to amplify a 242 base pair DNA fragment that was subjected to
heteroduplex SSCP analysis. The denaturing polyacrylamide gels were stained in
1.5XTBE containing a final concentration of 0.0075% (v/v) EtBr, for 20 minutes and
bands were visualised in the gel with UV light and subsequently photographed with
the GelDoc system (BioRad, Hercules, CA, USA). Termination cycle sequencing
was employed to confirm the presence/absence of the polymorphism. PCR products
were purified using a QfAquick" PCR Purification Kit (QIAGEN, GmbH, D-40724,
Hilden). Sequencing reactions were performed using a Perkin Elmer BigDye™
Terminator Cycle Sequencing Kit (PE Applied Biosystems, Warrington WA, 4SR,
Great Britain) and the forward primer as described in Table 3.01. These reactions
were run on an ABI 3100 (PE Applied Biosystems, Warrington WA, 4SR, Great
Britain) to determine their sequences. Sequences were analysed using the programs
Sequencing Analysis (V3.07) and BioEdit Sequence Alignment Editor (Hall, 1999).
Refer to Appendix B for a detailed protocol.
Genotyping of the CYP2D6*3 polymorphism was performed using the polymerase
chain reaction single strand conformation (PCR-SSCP) method of detection. In brief,
PCR was employed to amplify a 269 base pair DNA fragment that was subjected to
SSCP gel electrophoresis on 15% (w/v) polyacrylamide (1% cross linking) gels. The
gels were run in 1.5X TBE (Refer to Appendix D) at 4°C for 4 hours at 200V (Refer
to Appendix B for a detailed protocol of SSCP electrophoresis). The CYP2D6*3
SSCP gels were silver stained for visualisation of the bands (refer to Appendix C for a
detailed protocol for silver staining). Refer to Table 3.01 for primer sequences and
annealing temperatures.
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Table 3.01: A summary of the CVP polymorphisms genotyped in this study, the
sequences of the primers and the annealing temperatures (TA) of
the primers.
Primer* Method ofPolymorphism
Name Sequence (5'-3') TA Detection
Reference
(OC)
CYPIAlmsplF TAG GAG TCT TGT C allele
CYPIAlml CTCATGCCT creates an Huang et al.,
6235T>C 56 MspI 1999CAG TGA AGA GGTCYPIAlmspIR GTAGCCGCT restriction site
CYPIAlvalF GAA CTG CCA CTT G allele
CYPIAlm2 CAGCTGTCT creates a Huang et al.,
4889 A>G
56 HindII 1999GAA AGA CCT CCCCYPIAlvalR
AGCGGTCA restriction site
CYPIA2F GGA AGG TAT CAG A allele
CYPIA2 CAGAAAGCC destroys an Christiansen
-734C>A 66 ApaI et al., 2000GGC TCA TCC TTGCYPIA2R ACAGTGCC restriction site
CYPIBIF ACT TIG GCA AGC
Heteroduplex ss# 570246
CYPlBl AAAAGAGG
SSCP analysis (NCB I Assay
55 Termination8372 A>C CCC TIT TCA CCT cycle
ID)
CYPIBIR TTTCAGGA This studysequencing_
GAT GAG CTG CTA
CYP2D6-3F ACT GAG CCCCYP2D6*3 15%PAA Topic et al.,
2637 del A CCG AGA GCA TAC
56.5 SSCP analysis 2000
CYP2D6-3R TCGGGAC
GGT GTT CCT CGC
CYP2D6-5F GCGCTA TGCYP2D6*4 60
MvaIIBstNI Brown etal.,
1934 G>A CTC GGT CTC TCG digestion 2000
CYP2D6-5R CTCCGCAC
* ,Q!)The pnmers were all synthesised by IDT (Integrated DNA Technologies, Inc,
Coralville, lA, USA).
3.3.5 Statistical Analysis
Allele and genotype frequencies were calculated and graphed using Microsoft® Excel
2000. Separate analyses were conducted for each of the polymorphisms. Due to the
small sample sizes, Fisher's Exact Tests were favoured over conventional chi-square
goodness-of-fit tests. Tools for Population Genetic Analysis, TFPGA (Miller, 1997)
was used to perform Fisher Exact Tests on the data to determine whether significant
differences in genotype and allele frequencies were found between the various patient
groups and clinical subgroups and the controls. TFPGA uses a Markov-Chain method
to calculate unbiased estimates of P and a Fisher's combined probability test to
48
Stellenbosch University http://scholar.sun.ac.za
CHAPTER THREE
calculate multi-loci statistics (Raymond and Rousset, 1994). Sequential Bonferroni
corrections (Rice, 1989) were deemed necessary due to the multiple tests performed.
Significance prior to sequential Bonferroni corrections was accepted at P<0.05, and
after application of the sequential Bonferroni correction, significance was accepted at
P<0.00052. Tests for Hardy-Weinberg Equilibrium were performed using TFPGA
(Miller, 1997).
3.4 RESULTS
Lists of drugs considered unsafe for porphyria patients have been compiled but due to
the extensive nature of the lists and the fact that they change regularly due to new
,
information that becomes available, they have not been reported on in this study.
These lists aided in the selection of CYPs included in this study.
The frequency distributions of the different genotypes and alleles for the CYP 1A 1ml ,
CYPIA1m2, CYPIA2, CYPIBl, CYP2D6*3 and CYP2D6*4 polymorphisms in the
VP disease group and clinical subgroups and the controls are shown in Table 3.02 and
Table 3.03 respectively. A few specimens were not included in the analyses because
of the poor quality of the PCR product after repeated attempts of obtaining suitable
PCR products were made. The control population demonstrated Hardy-Weinberg
equilibrium for all the polymorphims genotyped in this study, except for the CYP1B1
8372 A>C polymorphism where a deviation was apparent. Differences in the
frequencies of the genotypes were observed between the clinical subgroups of VP
patients (Appendix I Graph L01-Graph 1.06). Differences in allele frequencies were
also observed between the clinical subgroups of VP patients (Appendix I Graph 1.07-
Graph 1.12). Apart from analysing the clinical subgroups, the total patients presenting
with acute attacks (AA+AASL) and the total patients presenting with skin lesions
(SL+AASL) were also analysed in a further attempt to clarify whether the CYP
polymorphisms modify the clinical expression of VP.
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Table 3.02: Genotype distributions of CYPIAlml, CYPIAlm2, CYPIA2,
CYPIBl, CYP2D6*3 and CYP2D6*4 polymorphisms in the
variegate porphyria disease group, clinical subgroups and
controls.
Genotype frequencies are indicated in (%), n indicates the sample size.
Variegate Porphyria
ril
'0
AA+ SL+ ..-AA SL AASL Asym Total c0AASL AASL U
n 4 12 6 8 10 18 30 83
CYPIAlml
11 6 5 7 17 23 66
Trr
(25.00) (91.67) (100.00) (62.50) (70.00) (94.44) (76.67) (79.52)
3 0 3 3 7 16
TIC
(75.00) (8.33) (0.0) (37.50) (30.00) (5.56) (23.33) (19.28)
0 0 0 0 0 0 0
CIC
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (1.21)
CYPIAlm2
4 12 6 8 10 18 30 77
AlA
(100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (93.90)
0 0 0 0 0 0 0 5
AlG
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (6.10)
0 0 0 0 0 0 0 0
GIG
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
CYPIA2
0 0 0 0 8
CIC
(0.0) (8.33) (0.0) (0.0) (0.0) (5.56) (3.33) (9.76)
7 2 4 3 9 14 29
CIA
(25.00) (58.33) (33.33) (50.00) (30.00) (50.00) (46.67) (35.37)
3 4 4 4 7 8 15 45
AlA
(75.00) (33.33) (66.67) (50.00) (70.00) (44.44) (50.00) (54.88)
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic
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Table 3.02 continued.
Variegate Porphyria
fil
AA+ SL+
'0
J.-AA SL AASL Asym Total =
AASL AASL 0U
n 4 12 6 8 10 18 30 83
CYPIBI
4 10 6 3 10 16 23 17
AlA
(100.00) (83.33) (100.00) (37.50) (100.00) (88.89) (76.67) (21.25)
0 2 0 5 0 2 7 53
AlC
(0.0) (16.67) (0.0) (62.50) (0.0) (1l.lI) (23.33) (66.25)
0 0 0 0 0 0 0 10
CIC
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (12.50)
CYP2D6*3
4 12 5 8 9 17 29 73
AlA
(100.00) (100.00) (83.33) (100.00) (90.00) (94.44) (96.67) (90.12)
0 0 0 8
Aldel
(0.0) (0.0) (16.67) (0.0) (10.00) (5.56) (3.33) (9.88)
0 0 0 0 0 0 0 0
del/del
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0)
CYP2D6*4
3 11 5 7 8 16 26 62
GIG
(75.00) (100.00) (83.33) (87.50) (80.00) (94.12) (89.65) (77.50)
0 0 0 16
GIA
(0.0) (0.0) (16.67) (0.0) (10.00) (5.88) (3.45) (20.00)
0 0 0 2 2
AlA
(25.00) (0.0) (0.0) (12.50) (10.00) (0.0) (6.90) (2.50)
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic
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Table 3.03: Allelic distributions of CYPIAlml, CYPIAlm2, CYPIA2, CYPIBl,
CYP2D6*3 and CYP2D6*4 in the variegate porphyria disease
group, clinical subgroups and controls.
Allele frequencies are indicated in (%), n indicates the sample size.
Variegate Porphyria
<Il
'0
AA+ SL+ ...-AA SL AASL Asym Total c0AASL AASL U
n 4 12 6 8 10 18 30 83
CYPIAlml
5 23 12 13 17 35 53 148
T
(62.50) (95.83) (100.00) (81.25) (85.00) (97.22) (88.33) (89.16)
3 0 3 3 7 18
C
(37.50) (4.l7) (0.0) (18.75) (15.00) (2.78) (11.67) (10.84)
CYPIAlm2
8 24 12 16 20 36 60 159
A
(100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (96.95)
0 0 0 0 0 0 0 5
G
(0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (3.05)
CYPIA2
9 2 4 3 11 16 45
C
(12.50) (37.50) (16.67) (25.00) (15.00) (30.56) (26.67) (27.44)
7 15 10 12 17 25 44 119
A
(87.50) (62.50) (83.33) (75.00) (85.00) (69.44) (73.33) (72.56)
CYPIBI
8 22 12 11 20 34 53 87
A
(100.00) (91.67) (100.00) (68.75) (100.00) (94.44) (88.33) (54.38)
0 2 0 5 0 2 7 73
C
(0.0) (8.33) (0.0) (31.25) (0.0) (5.56) (11.67) (45.63)
CYP2D6*3
8 24 11 16 19 35 59 154
A
(100.00) (100.00) (91.67) (100.00) (95.00) (97.22) (98.33) (95.06)
0 0 0 8
del
(0.0) (0.0) (8.33) (0.0) (5.00) (2.78) (1.67) (4.94)
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic
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Table 3.03 continued.
Variegate Porphyria
rIJ
'0
AA+ SL+ ...-AA SL AASL Asym Total =0AASL AASL U
n 4 12 6 8 10 18 30 83
CYP2D6*4
6 22 Il 14 17 33 53 140
G
(75.00) (100.00) (91.67) (87.50) (85.00) (97.06) (91.38) (87.50)
2 0 2 3 5 20
A
(25.00) (0.0) (8.33) (12.50) (15.00) (2.94) (8.62) (12.50)
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic
Significant differences in genotype distributions were obtained for the CYPIAlml
polymorphism, prior to Bonferroni correction, for the skin lesions group versus the
acute attack group of VP and for the acute attack and skin lesions (AASL) group
versus the acute attacks group (Table 3.04, indicated in red). Significant P-values
were observed for the CYPIBI genotype distributions for the disease group and all
the subgroups of VP versus the controls prior to correction (Table 3.04), with the
comparison between the acute attacks versus the controls becoming non-significant
after correction. The only exception to this was for the asymptomatic group versus
the controls. Significant differences were also observed for the CYPIBI genotype
distributions, prior to correction, for the acute attacks and skin lesions (AASL)
clinical subgroup, the total acute attacks group (AA+AASL) and for the total skin
lesion group (SL+AASL) versus the asymtomatic clinical subgroup (Table 3.04,
indicated in red). These results are interesting as neither of the acute attacks or skin
lesions clinical subgroup showed significant P-values when compared to the
asymtomatic group.
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Table 3.04: Fishers Exact P-values for genotype distributions of CYPIAlml,
CYPIAlm2, CYPIA2, CYPIBl, CYP2D6*3 and CYP2D6*4
polymorphisms
P-values
VPvs
Controls 1.0000
CYPIAlml CYPIAlm2 CYPIA2 CYPIBI CYP2D6*3' CYP2D6*4
0.09520.3204 0.3451 0.0000 0.7184
AAvs
Controls 0.0738
0.3093SL vsControls 0.7258
1.0000AASL vsControls 0.6109
0.1244Asym vs
Controls 0.4140
0.3511
AA+AASL
vs Controls 0.4897
0.4384SL+AASLvsControls 0.4173
0.4191
AA vsAsym 0.5442
SL vs Asym 0.2527
1.0000
1.0000
1.0000
1.0000
1.0000
0.5833
1.0000
1.0000
1.0000
0.3256
1.0000
0.7390
0.6794
0.5755
0.5756
0.7980
0.0041
0.0000
0.0004
0.5129
0.0000
0.0000
0.0830
0.0625
1.0000
0.5915
0.4905
1.0000
1.0000
1.0000
1.0000
1.0000
0.1613
1.0000
AASLvs
As m 0.2080 1.0000 0.6266 0.0306 0.4295 0.6871
AA+AASL
vs As 1.0000 1.00001.0000 0.6335 0.0061 1.0000
SL+AASLvs
As 0.0734
0.6643
SLvs AA 0.0267
1.0000
1.0000
1.0000
0.4524
0.0140
1.0000
1.0000
1.0000
0.5442
0.2669
AASLvs SL 1.0000 0.3526
AASLvsAA 0.0350 1.0000
1.0000
1.0000
0.5628
1.0000
0.5313
1.0000
0.3313
AA+AASL
vs SL+AASL 0.1175 1.0000 0.5107 0.5233 1.0000 0.4471
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic; Red value - P-value significant prior to sequential Bonferroni correction; Blue
value - P-value significant after Bonferroni correction
The results of the Fisher's Exact Test for the allele distributions gave similar results to
that of the genotype distributions. The same comparisons were significant except for
the acute attacks and skin lesion (AASL) clinical subgroup versus the asymptomatic
clinical subgroup that was non-significant for CYPIBI prior to Bonferroni correction.
CYPIBI comparisons between the acute attacks clinical subgroup and the acute
attacks and skin lesion (AASL) clinical subgroup versus the controls and the total
acute attacks (AA+AASL) clinical subgroup and the total skin lesion (SL+AASL)
clinical subgroup versus the asymptomatic clinical subgroup were all non-significant
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after the sequential Bonferroni correction was applied (Table 3.05, indicated in red).
Comparisons between the skin lesion (SL) clinical subgroup and the acute attacks and
skin lesions (AASL) clinical subgroup versus the acute attacks (AA) clinical subgroup
for CYPIAlml, became non-significant after the sequential Bonferroni correction
was applied. The P-values for these analyses are summarized in Table 3.05.
Table 3.05: Fishers Exact P-values for allele distributions of CYPIAlml,
CYPIAlm2, CYPIA2, CYPIBl, CYP2D6*3 and CYP2D6*4
polymorphisms
P-values
VPvs
Controls 1.0000
CYPIAlml CYPIAlm2 CYPIA2 CYPIBI CYP2D6*3' CYP2D6*4
0.49700.3282 0.7426 0.0000 0.7262
AA vs
0.0570
0.1351
Controls
SL vs
Controls 0.4753
1.0000
AASLvs
Controls 0.6113
1.0000
Asym vs
Controls 0.4040
0.7220
AA+AASL
vs Controls 0.4823
0.1353
SL+AASLvs
Controls 0.2118
0.1667
AA vsAsym 0.3579
SL vsAsym 0.2837
1.0000
1.0000
1.0000
1.0000
1.0000
0.5901
1.0000
1.0000
0.6828
0.3370
0.5215
1.0000
0.2927
0.6878
0.6254
0.5028
0.0102
0.0003
0.0012
0.3110
0.0000
0.0000
0.1286
0.0924
1.0000
0.5980
0.4822
1.0000
1.0000
1.0000
1.0000
1.0000
0.2763
0.5779
AASLvs
As 0.2383 1.0000 0.6724 0.0518 0.4298 1.0000
AA+AASL
vsAs 1.0000 1.00001.0000 0.6733 0.0113 1.0000
SL+AASLvs
As 0.0794
0.5367
SL vs AA 0.0398
1.0000
1.0000
0.7489
0.3778
0.0239
1.0000
1.0000
1.0000
0.2346
0.0621
AASLvs SL 1.0000 0.3485
AASLvsAA 0.0487 1.0000
1.0000
1.0000
0.2690
1.0000
0.5407
1.0000
0.3301
AA+AASL
vs SL+AASL 0.1281 1.0000 0.3319 0.5320 1.0000 0.1350
Key: AA- acute attacks; SL - skin lesions; AASL -acute attacks in combination with skin lesions;
Asym - asymptomatic; Red value - P-value significant prior to sequential Bonferroni correction; Blue
value - P-value significant after Bonferroni correction
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3.5 DISCUSSION
The South African variegate porphyria population, being a founder based population,
is a very valuable research tool that can aid the search for genetic factors that may
influence the clinical expression of the disease. Warnich et al. (2002), failed to
demonstrate any correlation between variation in the promoter region of PPOX with
clinical expression of VP. A need therefore exists to identify other genes that might
act as possible modifiers of clinical expression of VP.
The CYP genes are appropriate candidates fitting the role of potential modifiers of
clinical expression of VP very well, as they are responsible for the metabolism of
many medications and environmental pollutants. Porphyria patients are advised to
use medication with extreme caution and in many cases are advised to avoid certain
medications altogether due to the risk of the drugs precipitating an acute attack.
Administration of the sex hormones oestradiol, oestiol and oestrone is advised to
proceed only with extreme caution (SAMF, 2000) in patients suffering from
porphyria. CYPIAl, CYPIA2 and CYPIBI all participate in the metabolism and
hydroxylation of these hormones and polymorphism within these genes may lead to
altered function and activity of the encoded enzymes resulting in altered metabolism
of the hormone. The possibility also exists that these polymorphisms may be in
linkage disequilibrium with other regulatory elements elsewhere in the genes, and as
such may be responsible for altered expression or activity of the enzyme product.
CYP2D6 is responsible for the metabolism of many of the medications
contraindicated in VP and was therefore also included as a potential modifier.
Christiansen et al., (2000) has shown association with the AlA genotype of CYPIA2
and clinical manifestation of PCT, providing further evidence for the possible
modifying role the CYPs may play in the clinical expression of other porphyria types.
In this study we examined the frequency of 5 common CYP polymorphisms
(CYPIAlml, CYPIAlm2, CYPIA2 -734 C>A, CYP2D6*3 and CYP2D6*4) and a
recently described single nucleotide polymorphism (SNP) in the 3'UTR of exon 3 of
CYPIBI in VP patients compared to healthy controls (Table 3.02 and Table 3.03).
Uncorrected and corrected P-values are shown (Table 3.04 and Table 3.05) as
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uncorrected P-values may result in Type I errors, while corrected P-values may result
in Type II errors, due to the stringent, conservative nature of sequential Bonferroni
corrections (SISA, 2002). The necessity of Bonferroni corrections in association
studies is still uncertain and remains debatable.
CYPIAlml yielded significant differences for comparisons of genotype distribution
and allele frequencies involving the skin lesion (SL) clinical subgroup versus the
acute attack (AA) clinical subgroup and for the acute attack and skin lesion (AASL)
clinical subgroup versus the acute attack subgroup (AA) prior to Bonferroni
correction. The T-allele is the predominant allele in patients presenting with skin
lesions (Table 3.03) with only one out of twelve patients presenting skin lesions
having a single C-allele. This indicates a possible role for the T-allele in increasing
the susceptibility of a patient to develop skin lesions, while the C-allele may offer
protection against developing skin lesions. The observed frequency of the T-allele is
also greater than the frequency of the C-allele observed in the asymptomatic patients.
These patients may be protected from developing skin lesions by another allele or,
alternatively, environmental factors may influence the development of or protect
against the development of skin lesions in these patients.
We show that the TIC genotype ofCYPlAlml in the acute attacks subgroup ofVP is
increased compared to the control group. Although the P-value for this comparison is
marginally (P<0.08), increasing the number of patients included in a follow up study
may demonstrate statistical significance between the TIC genotype and the acute
attack of VP. The ml (CIC) genotype of CYPIAI represents a phenotype of high
inducibility (Peterson et al., 1991, Landi et al., 1994) and has been associated
experimentally with higher catalytic activity (Mucci et al., 2001). This increased
activity of the enzyme may alter the concentration and state of the relative metabolites
of its substrates. These alterations in metabolism may indeed have an effect on the
clinical expression of the acute attack of VP. Expression studies in a laboratory
model of VP are recommended to ascertain the effect that increased catalytic activity
of this enzyme has on the clinical expression of VP, especially the development of the
acute attack. A mouse model would be useful in achieving this as CYPIAI is
relatively conserved between humans and mice (Ingelman-Sundberg, 1998). A useful
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R59W heterozygous mouse model, for the biochemical phenotype of VP, is described
by Medlock et al. (2002). Studying this model may give insights into the pathogenic
mechanisms operative in the clinical expression of VP.
Our results show that the frequency of the AIA genotype of CYP 1B1 in all the clinical
subgroups of VP involving acute attacks and skin lesions is greatly increased
compared to the control group (Table 3.02). The frequency of the A-allele is
increased in all VP clinical subgroups including the total disease group compared to
that of the control group. Highly significant P-values were observed after Fisher's
Exact Tests in comparisons between VP patients (disease group and clinical
subgroups) and controls for both genotype and allele distributions (Table 3.04 and
Table 3.05). It is of extreme interest to note that significant values were observed for
the acute attack and skin lesion clinical subgroups when compared to either the
control group or the asymptomatic clinical subgroup. Significant differences were
observed for comparisons between the acute attacks and the skin lesions clinical
subgroups and the controls. The same is however not true for comparisons between
the acute attacks and the skin lesions clinical subgroups and the asymptomatic clinical
subgroup. The possibility exists that some of the asymptomatic patients have not yet
been exposed to agents known to precipitate the development of acute attacks or skin
lesions and therefore these patients may have been incorrectly classified. Some of the
significant P-values did, however, become non-significant after the sequential
Bonferroni correction was applied (P-values indicated in red in Table 3.04 and Table
3.05). It is interesting to note that the clinical symptom involved in the majority of
the comparisons that lost significance after the application of the Bonferroni
correction, was the acute attack. Diagnosis of the acute attack is partial to the
subjectivity of the consulting clinician and is further hampered as families that present
with the acute attack of VP, may encourage subsequent generations to avoid known
precipitating agents of the acute attacks. It is therefore possible that some of the
patients that should "genetically" present with acute attacks are missed. Diagnosis of
skin lesions on the other hand, is a much simpler, easier process.
Although definite conclusions cannot be made from this study due to the relatively
small number of patients included in the study, the difference in genotype and allele
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distributions between control and asymptomatic patients and patients presenting with
acute attacks, skin lesions or both are suggestive of an association between these
symptoms and the AIA genotype or A-allele of CVP 1B1. Evidence in support of this
conclusion is made even stronger by the observation that in all of the clinical
subgroups involving the presentation of acute attacks the frequency of the A-allele is
100.00%. This allele may therefore increase the patients' susceptibility to developing
acute attacks or it may be in linkage disequilibrium with other susceptibility loci
situated else where in the gene. The structure of the mRNA of this gene may be
altered due to this polymorphism, as it has been shown that variations in the 3'UTR of
a gene have the potential to alter the stem-loop structure of mRNA and as such affect
mRNA processing and stability (Williams et aI., 1994, Williams and Marzluff, 1995,
Dean et al., 2001 and Grzybowska et al., 2001). The observation that the control
population deviated from Hardy-Weinberg equilibrium for the CYPIBI
polymorphism necessitates the expansion of the control population. The reason for
this deviation is unknown.
Expression studies involving CYPIBI carrying these two alleles will have to be
performed to identify if one of the alleles (wild type or variant) carries higher activity
of the enzyme. Using a mouse model of VP is not recommended in this case, as there
is no notable homology between the rodent ortologue and the human CYPIBI
enzyme (Ingelman-Sundberg, 1998). The P-value observed for the comparison
involving the asymptomatic clinical subgroup and the controls for CYPIB1, was so
insignificant that it suggests further evidence that this SNP or a locus linked to it may
indeed participate in the modification of the clinical expression of VP. Our results
therefore "strongly" suggest that CYPIBI may be a major modifier gene of the
clinical expression of VP, as even with these small sample sizes extremely significant
P-values were observed.
CVP 1B1 is in a key position to be a modifier gene of the clinical expression of VP
due to its location in extrahepatic organs (Shimada et al., 1996, Hakkola et al., 1997)
including the skin (Sutter et al., 1994), where its expression is induced by UV light
(Katiyar et al., 2000), and the central nervous system (CNS), where its localisation at
the interface of the blood and brain suggests that this enzyme may act as an enzymatic
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barrier preventing the entry of chemicals into adjacent brain parenchyma (Rieder et
al.,2000). As the clinical expression ofVP involves the CNS and the skin, CYPIBI
may be responsible for the modification of the symptoms.
The results observed for the other CYP polymorphisms genotyped in this study all
rendered non-significant P-values. We show that the frequency of the AlA genotype
of CYPIA2 in the acute attack (AA), acute attack and skin lesion (AASL) and the
acute attack and acute attack + skin lesion (AA+AASL) clinical subgroups of VP are
increased when compared to the control group (P-values all non-significant). The
AIA genotype of this polymorphism is associated with the skin lesions observed in
patients with PCT (Christiansen et al., 2001). We would therefore have expected a
similar association with the skin lesions of VP. The ClA polymorphism located in the
non-coding region of CYPIA2 may be responsible for a differential binding of
regulatory proteins to the surrounding sequence leading to variations in the expression
level of CYPIA2 or it may be in linkage disequilibrium with regulatory loci
elsewhere in the gene. The AIA genotype represents a highly inducible genotype that
is associated with increased activity of CYPIA2 upon exposure to inducing agents
including smoking (MacLeod et al., 1998, Sachse et al., 1999). The highly inducible
genotype (AlA) of CYPIA2 may be a susceptibility factor for the development of
symptoms and may be induced by environmental factors that these patients are
exposed to. Increasing the number of patients included in this study may allow this
proposed effect to be observed.
The G-allele of CYPIAlm2 is very rare in our study populations with only 5 of 83
individuals of the control group having one copy of this allele. The substitution of a
G for an A in exon 7 of CYPIAI causes an amino acid change (lle to Val) in the
haem-binding region of the protein. The Val variant has almost two fold higher
catalytic enzyme activity than the Ile form (Landi et al., 1994, Autrup, 2000). It
seems that this polymorphism has no relevance in the South African VP population.
Mucci et al. (2001) reports that homozygotes of this allele are more common in
Japanese than Caucasian populations.
60
Stellenbosch University http://scholar.sun.ac.za
CHAPTER THREE
CYP2D6 plays an important role in the metabolism of many of the medications
contraindicated in porphyria patients and in the metabolism of opioids, used to' treat
an acute attack. We therefore screened Dur VP patients and healthy controls fDr two'
of the poor metaboliser genotypes (CYP2D6*3 and CYP2D6*4) of this gene. Our
data ShDWthat the frequency of the wild type alleles are far increased compared to' the
number of variant alleles in Dur populations (Table 3.03). Although not statistically
significant, there were slightly higher wildtype frequencies in the VP disease group
compared to' the controls. The frequency of the CYP2D6*4 A-allele in Dur healthy
controls was increased compared to' the frequency Dbserved by Topic et al., (2000) in
their healthy control group. This is indicative of the expected inter-ethnic difference
in allele frequencies. The number of patients included in this study was however
limited, therefore it is suggested that more patients be included in a follow up study to'
provide a clearer picture of the extent of correlation between VP (and its clinical
expression) and CYP2D6.
Although the numbers of patients included in this study are relatively small, the
results observed suggest that CYPIBI plays a more important role in the modification
of the clinical expression of variegate porphyria than the other CYPs studied. Itmay
be that CYPIAI, CYPIA2 and CYP2D6 are less significant modifiers of the clinical
expression of VP and that increasing the number of patients may give a truer
reflection of the role they play. It would be very interesting to' study the effects of
these polymorphisms on the clinical expression DfVP in other populations (Japanese,
Finnish, Turkish etc.) to' ascertain the relevance of Dur results compared to' results in
these populations, It may be possible that these polymorphisms exercise subtle
effects, increasing the susceptibility for certain clinical features that will only be
apparent under specific environmental conditions. Furthermore, the results we
obtained may be population specific Dr may be the result of an error due to' the small
sample size.
Although cytochrome P450s have been implicated as possible modifier genes of the
clinical expression of VP (VDnund zu Fraunberg et al., 2002), this is, to.the best of
Dur knowledge, the first study to' investigate the association between the CYPs and
VP. We have shown that the cyotochrome P450 genes, especially CYPIBI due to' the
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highly significant associations it displayed, are good candidates for modifying the
clinical expression of VP. Clinical expression of VP is complex and the possibility
exists that more than one gene plays a role in modifying it. Future studies using DNA
chip technology would enable the simultaneous identification of different alleles from
genes suspected of playing a role in the modification of the clinical expression of VP.
DNA chips have the potential to exert an enormous impact on the elucidation of the
possible multi-factorial modification of the clinical expression of VP. Looking
simultaneously at all of the pieces of the VP puzzle could, in future studies, greatly
increase our understanding of the relative roles played by genetics and the
environment in modifying clinical expression of variegate porphyria.
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Graph 1.01: Comparison of CYPlAlml genotype frequencies for variegate
porphyria patients (disease group and clinical subgroups) and
controls
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Graph 1.02: Comparison of CYPlAlm2 genotype frequencies for variegate
porphyria patients (disease group and clinical subgroups) and
controls
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Graph 1.05: Comparison of CYP2D6*3 genotype frequencies for variegate
porphyria patients (disease group and clinical subgroups) and
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porphyria patients (disease group and clinical subgroups) and
controls
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Graph 1.10: Comparison of CYP1Bl allele frequencies for variegate porphyria
patients (disease group and clinical subgroups) and controls
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Graph 1.11: Comparison of CYP2D6*3 allele frequencies for variegate
porphyria patients (disease group and clinical subgroups) and
controls
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Graph 1.12: Comparison of CYP2D6*4 allele frequencies for variegate
porphyria patients (disease group and clinical subgroups) and
controls
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CHAPTER FOUR
CYP POLYMORPHISMS IN TWO SOUTH
AFRICAN BREAST CANCER POPULATIONS:
AN ASSOCIATION STUDY
4.1 ABSTRACT
Breast cancer is one of the leading causes of death in women due to cancer. It is a
multifactorial disease and is neither purely genetic nor purely environmental. At 50 years of
age, risk of developing breast cancer is approximately 1 in 50, at 80 years of age, risk
increases to 1 in 10. Mutations in major cancer susceptibility genes identified to date, such as
BRCAI and BRCA2 are responsible for only 5-10% of all observed breast cancer cases. It is
believed that breast cancer may be the result of co-participation between common DNA
alterations and environmental exposures, including hormone replacement therapy
(oestrogen), smoking, absence of breast-feeding and contraception use. Polymorphisms in
enzymes involved with the metabolism of these environmental exposures, such as the
cytochrome P450 enzymes (CYP), are therefore expected to play an etiological role in breast
cancer. Four CYP polymorphisms (CYP1A1ml, CYP1A1m2, CYP1A2 -734 C>A and
CYP1B1 8372 A>C) were genotyped in two groups of breast cancer patients (29 Caucasians
and 67 of mixed ancestry) and healthy population-matched controls. Significant differences
in genotype distributions (P<0.0001) and allele frequencies (P<0.03) were observed between
the mixed ancestry breast cancer patients and the mixed ancestry controls for the CYP1Bl
8372 A>C polymorphism. Significant differences in allele frequencies were also observed
between the two control populations for the CYPIA1ml (P<0.02) and CYPIB1 8372 A>C
(P<0.03) polymorphisms. Differences in allele frequencies for the variant alleles were
observed between the two groups of breast cancer patients. These results emphasize the
importance of population-based risk assessment when genetic testing and counselling for
complex disease susceptibility is offered.
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4.2 INTRODUCTION
Breast cancer is the most prevalent cause of death due to malignancy in South African
women (SAPA, 10/10/2002). Breast cancer is a complex disease, as it is neither exclusively
genetically, nor exclusively environmentally developed. The role of changing environmental
factors in the development of breast cancer is indicated by a decrease in age of onset of the
disease (Kristensen and Berresen-Dale, 2000). The genetic basis of breast cancer does not
only result from the inheritance of specific rare mutations, but may be the result of inheriting
various relatively common mutations, with many genes each making a small contribution to
overall susceptibility (Campbell et al., 2000). Research is currently focused on the
identification of susceptibility genes i.e. genes that encode a product with which an
environmental agent may interact, causing an alteration of normal cellular functions and
critical life processes of the cell, leading ultimately to toxicity or malignancy (Nebert and
Roe, 2001). Allelic variants of genes encoding for drug metabolising enzymes, drug receptor
molecules and drug transporter genes are expected to be factors affecting enhanced or
reduced risk of cancer susceptibility and toxicity to drugs and environmental carcinogens
(Nebert, 1999).
Early age at menarche, late menopause, high serum or urine oestrogen levels and low levels
of sex hormone binding protein (that leads to a high availability of unbound oestradiol) have
been identified as risk factors for the development of breast cancer, suggesting a role for
endogenous and exogenous oestrogens in breast cancer development (Hankinson et al.,
1998). Oestrogens provide mitotic stimulation and promote tumour growth in breast cancer
(Huber et al., 2002). Hsu et al. (1991) has shown that upregulation of oncogenes by
oestrogen results in the stimulation of breast cancer cell proliferation while Tesarik et al.
(1999) attributes modulation of breast cancer cell apoptosis to oestradiol. Oestradiol
synthesis from cholesterol occurs in a number of enzymatic steps many of which are
catalysed by cytochrome P450 (CYP) enzymes.
Of all CYPs, CYP1B1 is expressed at the highest levels in breast cancer tissue (Kristensen
and Berresen-Dale, 2000) and has the strongest oestradiol activity (Mucci et al., 2001).
CYPIBI variants are associated with altered oestrogen metabolism (Mucci et al., 2001).
CYPIBI is therefore placed in a key position for mammary carcinogenesis due to the
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endogenous production of potentially carcinogenic catechol oestrogens and its ability to
metabolically activate exogenous procarcinogens (Bailey et al., 1998a). CYPIBI is also
important for the homeostasis of oestrogen in extrahepatic tissues such as the breast (Bailey
et al., 1998a), for transformation of xenobiotics (Huber et al., 2002) and is capable of
activating environmental procarcinogens and anticancer agents (Huber et al., 2002).
CYPIAl, a highly inducible enzyme (Coughlin and Piper, 1999), is said to be the principle
enzyme in the activation of cigarette-smoke and other environmental pollutants including, but
not limited to, polycyclic aromatic hydrocarbons (PAH), dioxin, aromatic amines,
polychlorinated biphenyls and nitrosamines (reviewed in Kristensen and Gut, 1994).
Heterocyclic aromatic amines (Morris and Seifter, 1992) and PAHs (Nagao et al., 1994) are,
in experimental models, potent mammary carcinogens. CYP1A1 is a participant in the first
step of procarcinogen conversion to DNA-binding, carcinogenic forms (Kawajiri, 1999) and
is involved in the metabolism of oestrogens (Mucci et al., 2001) and in oestrogen
hydroxylation (Huang et al., 1999b). CYPIAI is also involved in xenobiotic metabolism
(Huber et al., 2002). Polymorphism within CYPIAI may affect the distribution of the
relative metabolites of PAHs and oestrogen, and as such determine susceptibility to cancer
(Yager, 1996, Zhu and Conney, 1998). Exposure to cigarette smoke from a young age
combined with the ml or m2 polymorphism of CYPIAI (refer to Table 4.01) has been
suggested to increase risk of developing breast cancer (Kristensen and Berresen-Dale, 2000).
It is however unclear whether increased risk due to CYPIAI genotype is dependant on
exposure to environmental factors (Huber et al., 2002). As these two polymorphisms have
been associated with increased catalytic activity of the enzyme, it is suggested that
polymorphism present within this gene may have an effect on the rate of PAH activation or
may increase the concentration of oestrogen agonists and may therefore play a role in
hormone or tobacco-dependant cancers (Mucci et al., 2001). Great ethnic variation exists in
the genotype distributions ofCYPIAI polymorphisms (Huber et al., 2002).
CYPIA2 metabolises aromatic amine procarcmogens and is involved in hepatic and
extrahepatic oestrogen hydroxylation to a lesser extent than CYPIAI and CYPIBI (Hanna et
al., 2000). Differences in CYPIA2 mRNA levels were observed in a study by Nebert et al.
(1996) and the suggestion is made that these interindividual differences in expression may
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playa role in toxicity and cancer. CYPIA2 is one of the enzymes primarily responsible for
oestrogen hydroxylation in human liver (Martucci and Fishman, 1993).
In this association study, we evaluate the contribution of four SNPs (CYPIAlml,
CYPIAlm2, CYPIA2 -734 C>A and CYPIBI 8372 A>C) to a well defined clinical
endpoint in two well characterised South African breast cancer populations and relevant
control groups.
4.3 MATERIAL AND METHODS
4.3.1 Study Populations
Blood samples, from 96 breast cancer patients (29 Caucasian and 67 of mixed ancestry
(Nurse et al., 1985)) were collected at Tygerberg Hospital after clinical and pathological
evaluation and diagnosis of breast cancer was obtained. A baseline questionnaire collected
information on potential risk factors for breast cancer as well as lifestyle habits (e.g. smoking
status, alcohol consumption, cooking methods (oil, gas, electricity, fire)). Individuals
constituting the healthy control populations were randomly selected and consisted of 76
Caucasians and 80 individuals of mixed ancestry. All individuals participating in this study
gave their written informed consent. Ethical approval was obtained from the Ethics
Committee, Faculty of Health Sciences, University of Stellenbosch.
4.3.2 DNA Extraction
Total genomic DNA was extracted using a modified protocol of Miller et al. (1998) (refer to
Appendix A for a detailed protocol) and the extracted DNA was stored at -20°C until
genotype analysis.
4.3.3 Genotyping of Cytochrome P450 Polymorphisms
PCR-based RFLP assays were used to determine the CYPIAlml, CYPIAlm2 and CYPIA2
genotypes (refer to Appendix B for a detailed protocol). Genotyping of the CYPIBI
polymorphism was performed using the polymerase chain reaction heteroduplex single strand
conformation (PCR-hex SSCP) (Kotze et al., 1995) method of detection. The primers were
designed from the CYPIBI sequence (gi 17446619, NCBI) using the program Primer3
available online (Table 4.01). In brief, PCR was employed to amplify a 242 base pair DNA
78
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR
fragment that was subjected to heteroduplex SSCP analysis. The denaturing polyacrylamide
gels were stained in 1.5X TBE containing a final concentration of 0.0075% (v/v) EtBr, for 20
minutes and bands were visualised in the gel with UV light and subsequently photographed
with the GelDoc system (BioRad, Hercules, CA, USA). Termination cycle sequencing was
employed to confirm the presence/absence of the polymorphism. PCR products were
purified using a QfAquick'" PCR Purification Kit (QIAGEN, GmbH, D-40724, Hilden).
Sequencing reactions were performed using a Perkin Elmer BigDye™ Terminator Cycle
Sequencing Kit (PE Applied Biosystems, Warrington WA, 4SR, Great Britain) and the
forward primer as described in Table 4.01. These reactions were run on an ABI 3100 (PE
Applied Biosystems, Warrington WA, 4SR, Great Britain) to determine their sequences.
Sequences were analysed using the programs Sequencing Analysis (V3.07) and BioEdit
Sequence Alignment Editor (Hall, 1999). Refer to Appendix B for a detailed protocol.
Table 4.01: A summary of the CVP polymorphisms genotyped in this study and the
sequences and annealing temperatures (TA) of the primers.
Primer*
Method ofPolymorphism TA ReferenceName Sequence (5'-3') (CC) Detection
CVP 1A 1msp/F TAG GAG TCT TGT C alleleCYPIAlml CTCATGCCT creates an
6235 T>C CAG TGA AGA GGT
56 Mspl Huang et al., 1999bCYPIAlmsplR GTAGCCGCT restriction site
CYPIAlvalF GAA CTG CCA CTT G alleleCYPIAlm2 CAGCTGTCT creates a
4889 A>G GAA AGA CCT CCC
56 HindII Huang et al., 1999b
CYPIAlvalR AGCGGTCA restriction site
CYPIA2F GGA AGG TAT CAG A alleleCYPIA2 CAGAAAGCC 66 destroys an Christiansen et al., 2000-734 C>A
CYPIA2R GGC TCA TCC TTG
Apa!
ACAGTGCC restriction site
CYPlBIF ACT TIG GCA AGC
Heteroduplex ss# 570246 (NCB!
CYPIBI AAAAGAGG SSCP analysis Assay
8372 A>C 55 Termination ID)CCC TIT TCA CCT cycleCYPlBIR This studyTTTCAGGA sequencing
,®* The pnmers were all synthesised by IDT (Integrated DNA Technologies, Inc, Coralville,
lA, USA).
4.3.4 Statistical Analysis
Allele and genotype frequencies were calculated and graphed using Microsoft® Excel 2000.
Separate analyses were conducted for each of the polymorphisms. Due to the small sample
sizes, Fisher's Exact was favoured over conventional chi-square goodness-of-fit tests. Tools
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for Population Genetic Analysis, TFPGA (Miller, 1997) was used to perform Fisher Exact
Tests to determine whether significant differences in genotype and allele frequencies were
found between the various patient groups and the controls. TFPGA uses a Markov-Chain
method to calculate unbiased estimates of P and a Fisher's combined probability test to
calculate multi-loci statistics (Raymond and Rousset, 1994). Due to the conservative nature
of exact tests and the lack of multiple tests (Rice, 1989), Bonferroni corrections were not
deemed necessary (Louis and Dempster, 1987). Significance was accepted at P <0.05. Tests
for Hardy-Weinberg Equilibrium were performed using TFPGA (Miller, 1997).
4.4 RESULTS
The frequency distributions of the different genotypes and alleles for the CYP 1A 1ml,
CYPIAlm2, CYPIA2 and CYPIBI polymorphisms are shown in Table 4.02 and Table 4.03
respectively. A few specimens were not included in the analyses because of the poor quality
of the PCR product after numerous attempts were made to achieve suitable product.
Differences were observed in the frequencies of genotypes (Graph 11.01 - Graph 11.04) and
alleles (Graph 11.05 - Graph 11.08) between the two ethnic groups (Caucasian and mixed
ancestry). The Caucasian and mixed ancestry control populations demonstrated Hardy-
Weinberg equilibrium for all the polymorphims genotyped in this study, except for the
CYPIBI 8372 A>C polymorphism where a deviation was apparent.
80
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR
Table 4.02: Genotype distributions of CYPIAlml, CYPIAlm2, CYPIA2 and CYPIBI
polymorphisms for Caucasian and mixed ancestry breast cancer cases
and controls.
Caucasian Mixed Ancestry
Genotype Cases (%) Control (%) Cases (%) Control (%)
CYPIAlml
Trr 24 (82.76) 60 (78.94) 42 (64.62) 49 (62.03)
TIC 5 (17.24) 15 (19.74) 21 (31.31) 26 (32.91)
CIC 0(0.0) 1 (1.32) 2 (3.08) 4 (5.06)
n=29 n=76 n=65 n=79
CYPIAlm2
AlA 28 (96.55) 70 (93.33) 60 (92.31) 73 (92.41)
AlG 1 (3.45) 5 (6.67) 5 (7.69) 6 (7.6)
GIG 0(0.0) 0(0.0) 0(0.0) 0(0.0)
n=29 n=75 n=65 n=79
CYPIA2
CIC 2 (6.9) 8 (10.67) 8(12.31) 3 (3.9)
CIA 9 (31.03) 27 (36.0) 25 (38.46) 31 (40.26)
AlA 18 (62.07) 40 (53.33) 32 (49.23) 43 (55.84)
n=29 n=75 n=65 n=77
CYPIBI
AlA 6 (21.43) 16 (2l.91) 14 (22.22) 23 (29.11)
AlC 18 (64.29) 51 (69.86) 45 (7l.43) 24 (30.38)
CIC 4 (14.29) 6 (8.23) 4 (6.35) 32 (40.51)
n=28 n=73 n=63 n=79
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Table 4.03: Allele distributions of CYPIAlml, CYPIAlm2, CYPIA2 and CYPIBI
polymorphisms for Caucasian and mixed ancestry breast cancer cases
and controls.
Caucasian Mixed Ancestry
Allele Cases (%) Control (%) Cases (%) Control (%)
CYPIAlml
T 53 (91.38) 135 (88.80) 158 (84.04) 124 (78.48)
C 5 (8.62) 17(11.18) 30 (15.96) 34 (21.52)
CYPIAlm2
A 57 (98.28) 145 (96.67) 182 (96.81) 152 (96.20)
G 1 (1.72) 5 (3.33) 6 (3.19) 6 (3.8)
CYPIA2
C 13 (22.41) 43 (28.67) 54 (28.72) 37 (24.03)
A 45 (77.59) 107 (71.33) 134 (71.28) 117 (75.97)
CYPIBI
A 30 (53.57) 83 (56.85) 103 (56.59) 70(44.30)
C 26 (46.43) 63 (43.15) 79 (43.41) 88 (55.70)
Significant differences in genotype distributions (P<O.OOOl, Table 4.04) and allele
frequencies (P<0.03, Table 4.05) were observed between the mixed ancestry breast cancer
patients and the mixed ancestry controls for the CYPIBI 8372 A>C polymorphism.
Significant results were obtained for the two control populations for CYPIAlml (P<0.02,
Table 4.05) and CYPIBI (P<0.03, Table 4.05).
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Table 4.04: Fishers Exact P-values for genotype distributions of CYPIAlml,
CYPIAlm2, CYPIA2 and CYPIBI polymorphisms.
Controls
Breast Cancer Patients Caucasian Breast Caucasians Mixed AncestryCancer Patients
Caucasian 1.0000
Mixed Ancestry 0.2240 0.8749
Caucasian Controls 0.0680
Caucasian 1.0000
Mixed Ancestry 0.6593 1.0000
Caucasian Controls 1.0000
Caucasian 0.7675
Mixed Ancestry 0.5789 0.1829
Caucasian Controls 0.2760
Caucasian 0.6776
Mixed Ancestry 0.4457 0.0000
Caucasian Controls 0.0000
Polymorphism
CYPIAlml
CYPIAlml
CYPIA2
CYPIBI
Table 4.05: Fishers Exact P-values for allele distributions of CYPIAlml, CYPIAlm2,
CYPIA2 and CYPIBI polymorphisms.
Controls
Polymorphism Breast Cancer Patients Caucasian Breast Caucasians Mixed AncestryCancer Patients
Caucasian 0.801
CYPIAlml Mixed Ancestry 0.0871 0.766
Caucasian Controls 0.0195
Caucasian 1.000
CYPIAlml Mixed Ancestry 0.6663 1.000
Caucasian Controls 1.0000
Caucasian 0.388
CYPIA2 Mixed Ancestry 0.2327 0.1475
Caucasian Controls 0.3476
Caucasian 0.758
CYPIBI Mixed Ancestry 0.6269 0.0231
Caucasian Controls 0.0253
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A multivariate logistic regression analysis of the populations based on confounding factors
(history of breast feeding, use of contraception, hormone replacement therapy, number of
pregnancies and smoking) was not feasible due to the unavailability of suitably defined
control populations. However, Fisher exact tests were performed on the genotype and allele
frequencies of the breast cancer patients (across all populations) based on their history of
confounding factors, to determine if there was any significant association between a
genotype/allele and risk of breast cancer. These results are summarised in Table 4.06 and
Table 4.07. Some of the patients were excluded from this analysis due to an incomplete
history.
Table 4.06: Fisher Exact P-values for breast cancer patients' genotype frequencies
P-values
CYPIAlml CYPIAlm2 CYPIA2 CYPIBI
Breast feeding (no vs yes) 0.587 0.5799 0.292 0.183
Contraception use (no vs yes) 1.000 1.000 0.221 0.079
Hormone replacement therapy (no vs yes) 1.000 1.000 0.340 0.118
Number of pregnancies (<2 vs >=2) 0.635 0.111 0.866 0.545
Smoking (no vs yes) 0.527 0.428 0.392 1.000
Table 4.07: Fisher Exact P-values for breast cancer patients' allele frequencies
P-values
CYPIAlml CYPIAlm2 CYPIA2 CYPIBI
Breast feeding (no vs yes) 0.595 0.587 0.2697 0.170
Contraception use (no vs yes) 1.000 1.000 0.496 0.212
Hormone replacement therapy (no vs yes) 1.000 0.579 0.103 0.142
Number of pregnancies (<2 vs >=2) 0.804 0.116 0.691 0.467
Smoking (no vs yes) 0.688 0.434 0.196 1.000
4.5 DISCUSSION
The importance of low-penetrance susceptibility genes in the aetiology of cancer is now
emerging. Genes involved in carcinogen metabolism and DNA repair modestly increase the
risk for cancer in exposed individuals at perhaps low doses of carcinogens (Bartsch et al.,
2000). Population based studies are required to determine the frequency of polymorphisms in
the low-penetrating susceptibility genes as different ethnic groups often show different
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polymorphism characteristics (Huang et aI., 1999a,Nebert, 1999, Evans and Johnson, 2001,
Ingelman-Sundberg, 2001, Weber, 2001). Epidemiological and cell biology studies have
highlighted the contribution of oestrogen to the development of breast cancer. Oestrogen can
bind to DNA triggering damage (Yager et al., 1996, Cavalieri et al., 1997, Zhu and Conney,
1998) suggesting that oestrogen might be a complete carcinogen that can directly cause
genetic alteration and effect tumour initiation. In this study we examined the frequency of
three common CYP polymorphisms (CYPIAlml, CYPIAlm2, CYPIA2 -734 CIA) and a
recently described single nucleotide polymorphism (in the 3'UTR of exon 3 ofCYPIBI 8372
A>C) present in CYPs involved with oestrogen metabolism in breast cancer patients from
two different South African populations. Differences in genotype (CYPIAlml) and allele
(CYPIAlml and CYPIA2) frequencies were observed between the two population groups,
indicating the ethnic variability of these polymorphisms (Table 4.02 and Table 4.03). To the
best of our knowledge this is the first study to investigate the frequency of cytochrome P450
polymorphisms in mixed ancestry breast cancer patients and South African breast cancer
patients of European descent.
The genotypic distributions for CYPIAlml, CYPIAlm2, CYPIA2 and CYPIBI for the
Caucasian population were all very similar between the breast cancer patients and the
controls. The same is true for the allele frequencies. Although the numbers are small, this
may be an indication that no significant increase in risk of developing breast cancer is
associated with any of these polymorphisms in the Caucasian population. The mixed
ancestry population showed similar results for CYPIAlml, CYPIAlm2 and CYPIA2
genotypic and allele distributions. Significant differences were, however, observed for
comparisons between mixed ancestry breast cancer patients and mixed ancestry controls for
genotypic and allele distributions of the CYP1B1polymorphism.
We show that significant P-values were obtained for both genotype and allele distributions
for CYPIBI between mixed ancestry breast cancer patients and mixed ancestry controls
(Table 4.04 and Table 4.05). The CIC genotype frequency was notably higher for the mixed
ancestry controls than for the mixed ancestry breast cancer patients (Table 4.02). It is
therefore possible that possessing a double dose of the C allele may therefore decrease ones
risk of developing breast cancer. Although the numbers of patients included in this study are
too low to allow definite conclusions, the results obtained for the CYPIBI polymorphism in
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the mixed ancestry population are suggestive of an association between CYPIBI
polymorphism and increased risk of developing breast cancer in this population. The
possibility exists that this association may be spurious due to population substructures that
arise as a consequence of admixture linkage disequilibrium (the control population was found
to deviate from Hardy-Weinberg equilibrium for this polymorphism). By estimating
individual admixture it is possible to control for admixture as a confounder in association
studies of genetic factors with disease risk (McKeigue et al., 2000). Exclusion or control of
admixture as a possible confounding factor will be achieved by genotyping other population-
specific polymorphisms.
CYPIBI is over expressed in a wide variety of cancers (McKay et al., 1995, Murray et al.,
1997, McFadyen et al., 1999, Murray et aI., 2001) including breast cancer tissue (Kristensen
and Berresen-Dale, 2000). This raises questions about the functional role of CYPIBI in
tumours. An increase in CYPIBI expression might favour oestrogen catabolism
(Dasmahapatra et al., 2002) due to the fact that CYPIBI is responsible for the hydroxylation
of oestradiaol-l Zf (E2) (Spink et al., 2000). Further work is required to investigate the
mechanism by which CYPIBI modifies breast cancer risk. Williams et al. (1994), Williams
and Marzluff (1995), Dean et al. (2001) and Grzybowska et al. (2001) have reported that
variations in the 3'UTR of genes can alter the stem-loop structure of mRNA and can affect
mRNA processing and stability. Functional studies would be advantageous to investigate the
effect of this polymorphism on the mRNA and to determine the mechanisms by which altered
mRNA may influence risk of developing breast cancer. This polymorphism may, however,
be in linkage disequilibrium with functional polymorphisms elsewhere in this gene or in a
gene present on the same chromosome.
McFadyen et al. (2001) have demonstrated that CYPIBI may be a mechanism of anticancer
drug resistance, and conclude that the presence of CYPIBI in tumour cells may have an
important role in drug resistance. More research into the functions of CYPIBI is however
necessary to completely understand the role it plays in breast cancer risk, and how to
successfully manage it to reduce risk. Insignificant P-values were obtained for the genotype
and allele distributions for the Caucasian breast cancer patients and controls when analysing
CYPIBI.
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The results for the CYPIAlml polymorphism in the Caucasian groups were in accordance
with results of previous studies (Rebbeck et al., 1994, Ambrosone et al., 1995, Taioli et al.,
1995, Bailey et al., 1998b) all of which failed to show a significant association overall
between CYPIAlml polymorphism and Caucasian breast cancer risk. Taioli et al. (1995)
also reports a lack of association of the CYPIAlm2 polymorphism and breast cancer risk in
patients of Caucasian origin. An increased risk of breast cancer was however reported by
them for women of African-American descent. Itwould therefore be interesting to screen the
African populations present in South Africa for the CYPIAlml and CYPIAlm2
polymorphisms. These results may prove to be of great merit in the fight against breast
cancer.
The variant allele of CYPIA2, i.e. the A-allele was by far the most predominant allele
observed in our study in both the breast cancer group and the control group of both
populations. In a case-control study involving South African variegate porphyria patients and
controls, the A allele of CYPIA2 was also more frequently observed than the wildtype C
allele (This study, Chapter Three). This finding is indicative of the ethnic variation observed
for the cytochrome P450 genes. The Af A genotype presents a highly inducible genotype of
this enzyme, and it has been shown that smoking further induces activity ofCYPIA2 (Sachse
et al., 1999). We showed a non-significant P-value for the comparison between breast cancer
patients with a history of smoking and those without a history of smoking for CYPIA2.
However it would be of more value to investigate the effect of smoking on breast cancer risk
by comparing breast cancer smokers to healthy control smokers. This was however not
possible in this study due to the limited information available about the control samples.
Studying the effects of confounders (absence of breast feeding, contraception use, hormone
replacement therapy, number of pregnancies and smoking status) on the risk of breast cancer
was hampered by the limited information available regarding the individuals included in the
control population. It is suggested that in future studies, control populations included in the
studies need to be as well defined as the individuals making up the disease population.
Analysis of the genotype distribution for contraception use among the breast cancer patients
for CYPIBI rendered an insignificant, yet encouraging P-value (Table 4.06). A follow up
study will investigate the effect of different contraceptives (oral versus injection and
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oestrogen versus progesterone) on the risk of breast cancer and these results should prove to
be very informative.
Our data did not support a substantial interaction effect between either of the CYP
polymorphisms and the risk of breast cancer overall. However it seems that the CYPIBI CIC
genotype may be a protective factor for decreased risk of breast cancer in the mixed ancestry
population. These results will be confirmed in a resampled mixed ancestry breast cancer
group.
It should be emphasized that it is absolutely necessary to genotype individuals from each
population represented in South Africa for CYP polymorphisms, as each population is
unique. Data such as this would be of great value to clinicians and pharmacists, as it will aid
in the elucidation of the differential response to medication among the South African
population.
A complete understanding of the aetiological role of oestrogen in breast cancer will, however,
require studies evaluating the roles of genes involved in oestrogen metabolism and the extent
to which oestrogen exposure modifies the associations of these genes with breast cancer risk.
Genetic polymorphisms have been found in phase I and phase II drug metabolising enzymes,
drug transporters and drug receptors, therefore, it is likely that risk assessments would
become more sensitive and reasonable if polymorphisms in all categories of enzymes were
taken into consideration as biomarkers for breast cancer risk.
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CONCLUSIONS
The applications of pharmacogenomics in research and drug development are vast, but not
straight forward. In order to have the most useful outcome, pharmacogenomic studies need
to be optimally designed. This includes sufficient characterisation of the patient and control
groups, and sufficient numbers of participants that are all thoroughly phenotyped. It is
recommended that different ethnic groups are genotyped as ethnic specificity may be useful
to improve diagnosis and clinical care of patients by providing information about the
structure of genes and regulatory pathways that may cause an altered response in that specific
population (Nebert, 1999, Evans and Johnson, 2001, Weber, 2001).
Benefits of pharmacogenomics for industry include the reduction of clinical trial sizes, which
may be limited to only genetically defined subpopulations. Screening the drugs for possible
interactions with polymorphic enzymes early in the development process has the potential to
reduce problematic dosing of future drugs due to the fact that fewer drugs that are substrates
for polymorphic enzymes will be released to the commercial market.
5.1 NEW TECHNOLOGY
With the development of newer methods of molecular analysis to detect DNA
polymorphisms, such as DNA chip technology, genotyping screening approaches are
increasingly becoming feasible. DNA chips are becoming increasingly important in
pharmocogenetics as they are used as research tools to screen drug candidates for the
development of new therapies and to score individuals and populations for polymorphisms
suspected of playing a role in drug susceptibility. They will however not reach their full
potential in pharmacogenomic testing until their cost has been reduced, they have greater
robustness and reliability and have improved production (Weber; 2001).
Once a polymorphism has been defined in a gene, functional significance of the
polymorphism requires demonstration. This introduces the field of functional genomies
(McKusick, 1997) in which genetically manipulated animals will be phenotyed to determine
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the biological function of the particular polymorphic gene. This experimental approach in
itself involves many new technologies (Ohlstein et al., 2000) including in vivo imaging, mass
spectrometry and microarray hybridization.
Single strand conformation polymorphism and restriction enzyme digests were the methods
of choice for polymorphism detection in these studies. These techniques are not without
limitations, including their laborious and tedious nature and the relatively small amount of
data that one is able to collect from many hours of work. DNA chip technology would have
greatly increased the amount and speed of data collection from this study, as it would have
enabled the screening of further polymorphisms in additional CVP genes. Technology such
as the DNA chip is currently not freely available on the local market and is very expensive.
5.2 VARIEGATE PORPHYRIA
Von und zu Fraunberg et al. (2002) suggest that cytochrome P450s are good candidates for
modifying porphyrin metabolism and variegate porphyria phenotype. The function of CYPs
may be decreased by an insufficient supply of haem in porphyria patients. To the best of our
knowledge, this is the first study to investigate the association of CVP polymorphisms with
the clinical expression of VP. Christiansen et al. (2000) has, however, performed a similar
study in porphyria cutanea tarda patients investigating the association of a CYPIA2
polymorphism with clinical expression.
In Chapter 3 of this study we demonstrate a lack of association between 4 (CYPIAlm2,
CYPIA2, CYP2D6*3 and CYP2D6*4) of the polymorphisms genotyped in this study and
clinical expression of VP. This may be the result of a sample size with too low numbers to
allow for the effect of the polymorphisms to be successfully observed, or may indicate that
the polymorphisms are simply not involved with modifying the clinical expression of VP.
Future haplotype studies on the VP families may be useful in elucidating the role of these
polymorphisms on the clinical expression of VP.
Two of the polymorphisms (CYPIAlml and CYPIBI 8372 A>C) genotyped in this study
did, however, demonstrate association with clinical expression ofVP. Although some of the
P-values for the comparisons became non-significant after the Bonferroni correction was
applied, sufficient evidence is provided to suggest a possible role for these CYPs in
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modifying the clinical expression of VP. We have shown significant association of the
CYPIBI 8372 A>C polymorphism with all the clinical subgroups of VP expressing
symptoms. The frequency of the A-allele in the subgroups expressing acute attacks is 100%,
a clear indication that this allele may indeed increase a patients' susceptibility to developing
an acute attack. Strong evidence is provided to suggest that CYPIBI may be a modifier of
the clinical expression of VP even with the low numbers of patients included in the study.
Further we observed significant differences in genotype and allele frequencies, prior to
Bonferroni correction, between the skin lesion (SL) and the acute attack (AA) clinical
subgroups, and the acute attack and skin lesion (AASL) and the acute attack clinical
subgroups (AA) for CYPIAlml, further implicating CYPs as candidate modifier genes of
VP clinical expression. It seems that the T-allele of this polymorphism may increase a
patients' susceptibility to developing skin lesions or that the C-allele may offer protection to
developing skin lesions.
This study has provided evidence in support of the suggestion that CYPs are candidate genes
for modifying VP clinical expression. Effective use of a mouse model of VP will enhance
studies investigating the effect of increased catalytic activity of CYPIAI on the clinical
expression of VP. Future studies would also include functional studies to determine whether
the CYPIBI polymorphism alters the expression of the gene due to it possibly having an
effect on the mRNA structure. One would also have to investigate whether linkage
disequilibrium is present between this polymorphism and other functional polymorphisms in
CYPIBI or in another gene on the same chromosome. Haplotype studies on the variegate
porphyria families will also increase our knowledge about the effect of CYP polymorphisms
on the clinical expression of VP. Studies in other populations are required to confirm our
findings and to determine the molecular mechanisms involved in clinical expression of VP in
those populations.
This study has, using a rather small study population, shown that CYPs may be genes
responsible for modifying the clinical expression ofVP to varying degrees. A Pandora's box
of questions regarding the possible effects that these genes have on the clinical expression
and the mechanisms involved with modifying expression of this disease has been opened -
questions that will hopefully be successfully answered in future studies. Future studies
investigating the role of CYPs in the development of symptoms, may find reasons explaining
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the lack of uniformity in the severity of the symptoms observed. Polymorphisms within these
CYP genes may potentially be used as markers for clinical expression of symptoms and
susceptibility to developing various clinical symptoms of VP.
5.3 BREAST CANCER
Bartsch et al. (2000), suggest that the future challenge of molecular epidemiological studies
involving cancer patients will be to analyse individuals that are exposed to carcinogens for a
combination of genotypes associated with susceptibility to cancer due to the fact that cancer
is a largely preventable disease. Establishment of risk profiles for individuals and subgroups
in known exposure situations will be aided by studies that integrate biomarkers for
carcinogen exposure, early biological effects and susceptibility. This study (Chapter 4) is
significant in that it is to the best of our knowledge, the first study to determine the
frequencies of CYP polymorphisms in the mixed ancestry population of South Africa and the
breast cancer population of South Africa as a whole. The results that were obtained will be of
great importance to the development of breast cancer risk profiles for this population. Our
results have emphasized the large inter-ethnic differences in allele frequencies in CYP genes
observed throughout the world.
In Chapter 4 of this study, we demonstrate non-significant results for three of the
polymorphisms (CYPIAlml, CYPIAlm2 and CYPIA2) genotyped in this study. This may
be the result of a sample size with too low numbers to allow for the effect of the
polymorphisms to be successfully observed, or may indicate that the polymorphisms are
simply not involved with modifying the risk of breast cancer in the South African
populations.
One of the polymorphisms (CYPIBI 8372 A>C) genotyped in this study did, however,
demonstrate association with increased risk of breast cancer in the mixed ancestry population.
This polymorphism, situated in the 3'UTR of exon 3 of the CYPIBI gene, may have an
effect on the mRNA structure and as such alter the expression of the gene. The possibility
also exists that this polymorphism may be in linkage disequilibrium with another functional
polymorphism in CYPIBI or a functional polymorphism in another gene situated nearby on
the same chromosome. Studies in other populations are required to confirm our findings.
Since the mixed ancestry control population deviated from Hardy-Weinberg equilibrium, it is
102
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FIVE
suggested that an alternative control population be genotyped and included in this study.
Controling for admixture as a confounder is also suggested.
It is unfortunate that all the relevant lifestyle information was not available for the control
individuals included in this study, as this would have added more depth to the study.
Stratification of the participants would have been possible, and as such, more knowledge
would have been gained regarding the various confounding factors of breast cancer in the two
South African populations studied. The results were however encouraging, and future studies
will investigate the involvement of additional CYPs on the risk of developing breast cancer,
in these and other populations unique to South Africa, in an attempt to develop risk profiles
for the South African populations. The resources that are required to conduct such studies
successfully necessitate large collaborations between epidemiologists, molecular biologists
and clinicians. These collaborations have been realised between the academics of the
University of Stellenbosch and scientists from the private sector. Participation like this will
help foster a deeper understanding into the complexity of breast cancer in the unique
populations of South Africa.
5.4 CHALLENGES AND FUTURE PROSPECTS OF
PHARMACOGENOMICS
Incorporation of genetic technologies into mainstream medicine will raise many Issues
including financial, ethical, legal, social and operational questions. Many of these questions
will touch on the core values, principles and ethical beliefs of the population. Bioethics is
therefore becoming increasingly important in the regulation and future of human genetic
technologies. If we are to benefit from these technologies, it is essential that public support
for the technologies is gained and that social and ethical implications and concerns are
addressed thoroughly.
Focused genome wide scans for polymorphisms associated with disease risk or drug response
will be aided by technological advances. Data generated from these scans, will aid clinicians
in making preventative health and prospective treatment decisions. The end result will be the
optimal selection of medications and their dosages based on the individual patient and will
not rely on average experiences from the global population of patients with a similar
diagnosis.
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TOTAL GENOMIC DNA ISOLATION FROM WHOLE BLOOD
A modified protocol of Miller et al. (1998) was followed to extract total genomic
DNA from whole blood.
Whole blood was collected in glass tubes containing ethylenediamine tetra-acetic acid
(EDTA, ClOHI6N20S)as the preservative. The blood was stored at 4°C until the DNA
extraction was performed the following day. If the extraction was unable to proceed
the day following the collection of the blood sample, the blood was stored at -20°C
until genomic DNA was extracted.
The tube containing the thawed blood was shaken and the contents poured into a 40ml
centrifugation tube (Greiner Labortechnik, Kremsmuenster, Austria). The EDTA tube
was rinsed out with 30ml cold lysis buffer (8.3mg/ml ammonium chloride (N~CI),
1.lmg/ml potassium hydrogen carbonate (KHC03), 25Jlg/ml EDTA, pH 7.4) and this
was added to the blood in the 40ml tube. This mixture was incubated on ice for 15
minutes with gentle inversion every 5 minutes. The mixture was centrifuged at 1500
rpm, at 4°C for 20 minutes (Beckman Avanti 30™, Beckman Coulter, Inc). The
supernatant was discarded and the pellet was resuspended in 10ml phosphate buffered
saline solution (PBS) (6mg/ml potassium chloride (KCI), 24mg/ml sodium chloride
(NaCl). 3.42mg/ml di-sodium hydrogen orthophosphate anhydrous (Na2HP04),
0.6mg/ml potassium dihyrdrogen orthophosphate (KH2P04)). This mixture was
centrifuged at 1500 rpm, at 4°C for 10 minutes and the supernatant was once again
discarded. The pellet was resuspended in 3ml nuclear lysis buffer (12.11mg/ml
tris(hydroxymethyl)aminomethane ((CH20H)3CNH2-CI), 23.4mg/ml NaCl, 0.6mg/ml
EDTA, pH 8.2), 30JlI proteinase K (10mg/ml) (Roche Diagnostics Corporation,
Indianapolis, IN, USA), and 150JlI 20% (w/v) sodium dodecyl sulfate (SDS). This
mixture was shaken well and incubated in a 50°C water bath overnight.
One milliliter 6M NaCl was added to the overnight incubation. This was followed by
a vigorous one minute shake, after which the mixture was centrifuged at 2500 rpm, at
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21°C for 15 minutes. The supernatant was transferred to a new 40ml tube (Greiner
Labortechnik, Kremsmuenster, Austria) taking care to leave the foam and pellet
behind. After a 15 second shake, this was centrifuged at 2500 rpm, at 21°C for 15
minutes. The supernatant was subsequently transferred to a 30ml glass Corex tube
(USA) taking note of the volume. Extreme caution must be exercised when
transferring the supernatant to avoid any contamination by the foam or the pellet.
Two 2 volumes of cold 100% (v/v) ethanol (EtOH) was added to the aqueous phase
and the tube was covered with Parafilm®(American National Can™, Menasha, WI,
USA). This was allowed to stand until a white spool formed and rose to the top of the
solution. The spool was transferred to a 1.5ml Safe Lock Eppendorf'" tube
(Eppendorf, Hamburg, Germany) with an innoculation needle (Looplast", LP ltaliana
SPA, Milan, Italy). The DNA was washed with 300JlI 70% (v/v) EtOH and this
mixture centrifuged at 14000 rpm, at 4°C for 5 minutes (Beckman GS-15R, Beckman
Coulter, Inc). The 70% EtOH was poured off and the pellet was allowed to air dry.
The pelleted DNA was resuspended in 250JlI sterile SABAX water (Adcock Ingram,
Johannesburg, RSA) overnight. DNA concentration and purity was determined by
running aliquots of the extracts on a 1% (w/v) agarose gel (stained with 0.0075% (v/v)
EtBr, IX TBE (refer to Appendix D) running buffer) with Lamda DNA (Promega
Corporation, Madison, WI, USA) standards. Lamda standards of 10ng/JlI,20 ng/ul,
40 ng/ul, 60 ng/ul and 80ng/JlI were loaded. The gel was run at 80V for thirty
minutes. Bands were visualised in the gel with UV light and were subsequently
photographed with the GelDoc system (BioRad, Hercules, CA, USA). The
concentration of the DNA was determined and it was subsequently diluted to 20-
30ng/JlI,aliquoted and stored at -20°C.
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GENOTYPING TECHNIQUES
CYPIAlml, CVPIAlm2, CYPIA2 and CYP2D6*4
Genotyping of the CYP1A1ml (6235 T>C, Msp! polymorphism), CYP1A1m2 (4889
A>G, IleNal substitution), CYP1A2 (-734 C>A) and CYP2D6*4 (1934 G>A)
polymorphisms was successfully performed using the polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP) (Kristensen et al., 2001)
method of detection. In brief, DNA fragments were amplified using PCR and the
primers described in Table 3.01 and Table 4.01. The reaction mixtures contained
approximately 20ng of genomic DNA, 20.0 11M of the forward primer, 20.0 11M of the
reverse primer, 200 11M of each dNTP (Promega Corporation, Madison, WI, USA),
0.5 units of Taq polymerase (BIOTAQ™ DNA Polymerase, Bioline, Springfield, NJ,
USA) and a final concentration of 1.0mM (CYP1A1ml and CYP1A1m2) or 1.5mM
(CYP1A2 and CYP2D6*4) MgCh in a total volume of 25.0111. PCR was performed at
95°C for five minutes for the initial denaturation, followed by thirty-five cycles of
denaturation at 95°C for thirty seconds, annealing at TA(refer to Table 3.01) for thirty
seconds, and extension at 72°C for one minute. This was followed by a ten minute
extension at 72°C after which the samples were held indefinitely at 4°C. All PCR
reactions were performed in a Perkin Elmer GeneAmp PCR system 9600 (Applied
Biosystems, Warrington, WA, USA).
An aliquot of 15111of PCR product was digested with I III of the relevant restriction
enzyme: CYP1A1ml with Msp! (Roche Diagnostics Corporation, Indianapolis, IN,
USA) (recognition sequence: 5'- C!CGG -3'), CYP1A1m2 with Hindll (Roche
Diagnostics Corporation, Indianapolis, IN, USA) (recognition sequence: 5'-
GT(T/C)!(AlG)AC -3'),CYPIA2 with Apa! (Promega Corporation, Madison, WI,
USA) (recognition sequence: 5' - GGGCC.!,C- 3') and CYP2D6*4 withMva! (BstNl)
(Promega Corporation, Madison, WI, USA) (recognition sequence: 5'- CC!AGG -
3') in a reaction with 2.5111reaction buffer in a total volume of 20111. The PCR
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products were digested at 37°C overnight according to the conditions on the package
insert provided with the restriction enzyme and enzyme buffer.
On completion of the digest, the products of the restriction enzyme digest were run on
a 3% (w/v),IX TBE (refer to Appendix D) agarose gel (CYPIAlml, CYPIAlm2 and
CYP2D6*4) at 60V for 2.5 hours or a 1% (w/v),IX TBE (refer to Appendix D)
agarose gel (CYPIA2) at 60V for 1.5 hours. Five microlitres of 6x loading dye (refer
to Appendix D) were added to each digest and 15.0111of this mixture was loaded to
the gel. The bands were stained with ethidium bromide (EtBr) added to the agarose
gel mix (final concentration 0.0075% v/v). A 100 bp ladder (Promega Corporation,
Madison, WI, USA) served as the molecular size marker (3.5 III ladder + 3.0 III 6x
loading buffer). Bands were visualised in the gel with UV light and subsequently
photographed with the GelDoc system (BioRad, Hercules, CA, USA, Hercules, CA,
USA, Hercules, CA, USA). Three different genotypes were defined for each of the
polymorphism, being the homozygous wild-type, the heterozygous and the
homozygous variant genotypes. Refer to Table B.OI for the respective genotypes for
each of the polymorphisms.
Table B.Ol: Definition of the genotypes of the CYPlAlml, CYPlAlm2,
CYPlA2 and CYPlBl polymorphisms.
Genoty~e
Polymorphism Homozygous Heterozygous Homozygous
Wildty~e Variant
CYPIAlml TIT TIC CIC
CYPIAlm2 AlA AlG GIG
CYPIA2 CIC CIA AlA
CYPIBI AlA AlC CIC
CYP2D6*3 AlA Aldel del/del
CYP2D6*4 GIG GIA AlA
CYPlBl
Genotyping of the AlC polymorphism present in the 3' UTR of exon 3 of CYP IB I
(8372 A>C) was successfully performed using the polymerase chain reaction single
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strand conformation polymorphism (PCR-SSCP) (Kristensen et aI., 2001) method of
detection. In brief, primers were designed from the CYP 1B1 sequence (gi 17446619,
NCBI) using the program Primer3 available online. PCR was employed to amplify a
242 base pair DNA fragment. The reaction mixture contained approximately 20ng of
genomic DNA, 0.8 ~M of the forward primer, CYPIBIF, 0.8 ~M of the reverse
primer, CYPIBIR, 200 ~M of each dNTP (Promega Corporation, Madison, WI,
USA), 1.0 units of Taq polymerase (BIOTAQ™ DNA Polymerase, Bioline,
Springfield, NJ, USA) and a final concentration of l.5mM MgCh in a total volume of
25.0~l. PCR was performed at 95°C for five minutes for the initial denaturation,
followed by thirty-five cycles of denaturation at 95°C for thirty seconds, annealing at
55°C for thirty seconds, and extension at 72°C for thirty seconds. This was followed
by a ten minute extension at 72°C after which the samples were held indefinitely at
4°C. All PCR reactions were performed in a Perkin Elmer GeneAmp PCR system
9600 (Applied Biosystems, Warrington, WA, USA). Refer to Table 3.01 for the
primer sequences and annealing terperatures.
SSCP
Five microlitres of formamide denaturing loading dye (refer to Appendix D) was
added to each PCR product and this mixture was subsequently denatured at 98°C for 8
minutes, before snap cooling on ice. Fifteen microlitres of this mixture were loaded
on a 15% (w/v) polyacrylamide (PAA) (1% cross-linking) 103 X 98mm (Mighty
Small, Hoefer Pharmacia Biotech Inc, BioRad, Hercules, CA, USA, Hercules, CA,
USA) SSCP gel. The gels were run at 200V, at 16°C, for 4 hours. The gels were
stained in 1.5X TBE buffer (refer to Appendix D) containing a final concentration of
0.0075% (v/v) EtBr for 20 minutes and bands were visualised in the gel with UV light
and subsequently photographed with the GelDoc system (BioRad, Hercules, CA,
USA).
SSCP-Heteroduplex
Samples that showed band differences were subjected to another round of PCR
(conditions as above) and were then run on 37cm X 16.5cm denaturing heteroduplex
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SSCP gels (Kotze et al., 1995). Five microlitres of formamide denaturing loading dye
were added to each PCR product and this mixture was subsequently denatured at 98°C
for 5 minutes, before snap cooling on ice. Fifteen microlitres of this mixture were
loaded to a 15% (w/v) PAA, 1% (w/v) urea ((NH2)2CO), 1% cross-linking
heteroduplex SSCP gel. The gels were run at 300V, at 4°C overnight. The gels were
removed from the electrophoresis apparatus and were stained in 1.5X TBE buffer
(refer to Appendix D) containing a final concentration of 0.0075% (v/v) EtBr for 20
minutes and bands were visualised in the gel with UV light and subsequently
photographed with the GelDoc system (BioRad, Hercules, CA, USA).
Samples with identical band patterns (SSCP and heteroduplex) were identified and
representatives from each band pattern were sequenced to determine the absence or
presence of the polymorphism. PCR products were purified using a QIAquick®PCR
Purification Kit (QIAGEN, GmbH, D-40724, Hilden). Sequencing reactions were
performed using a Perkin Elmer BigDye™ Terminator Cycle Sequencing Kit (PE
Applied Biosystems, Warrington WA, 4SR, Great Britain) and forward primer as
described in Table 3.01. These reactions were run on an ABI 3100 (PE Applied
Biosystems, Warrington WA, 4SR, Great Britain) for sequencing. Sequences were
analysed using the programs Sequencing Analysis (V3.07) and BioEdit Sequence
Alignment Editor (Hall, 1999).
CYP2D6*3
Genotyping ofCYP2D6*3, the single base deletion (A2637)in exon 5 ofCYP2D6 was
successfully performed using the polymerase chain reaction single strand
conformation polymorphism (PCR-SSCP) (Kristensen et al., 2001) method of
detection. In brief, PCR amplification of a 269 base pair DNA fragment was
performed using the primers described in Topic et aI., (2000) (Refer to Table 3.01 for
the primer sequences). The reaction mixture contained approximately 20ng of
genomic DNA, 0.8 J..lMof the forward primer, CYP2D6-3F, 0.8 J..lMof the reverse
primer, CYP2D6-3R, 200 J..lMof each dNTP (Promega Corporation, Madison, WI,
USA), 1.25 units of Taq polymerase (BIOTAQ™ DNA Polymerase, Bioline,
Springfield,NJ, USA) and a final concentration of 0.8mM MgCh in a total volume of
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25.0J..l1.PCR was performed at 92°C for ten minutes for the initial denaturation,
followed by thirty-eight cycles of denaturation at 92°C for forty-five seconds,
annealing at 56.5°C for thirty seconds, and extension at 72°C for thirty seconds. This
was followed by a ten minute extension at noc after which the samples were held
indefinitely at 4°C. All PCR reactions were performed in a Perkin Elmer GeneAmp
PCR system 9600 (Applied Biosystems, Warrington,WA, USA).
Five microliters of formamide denaturing loading dye (refer to Appendix D) was
added to each PCR product and this mixture was subsequently denatured at 98°C for 8
minutes, before snap cooling on ice. Six microliters of this mixture was loaded on a
15% (w/v) PAA (1% cross linking) Mighty Small (103 X 98mrn) (Hoefer Pharmacia
Biotech Inc) SSCP gel. The gels were run in 1.5X TBE (refer to Appendix D), at
200V, at 4°C, for 4 hours. The gels were silver stained for visualisation of bands
(refer to Appendix C for a detailed silver staining protocol).
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SILVER STAINING OF POLYACRYLAMIDE GELS
After removing the polyacrylamide gels from the plates, they were placed in a plastic
container and were covered with fixing solution (10% (v/v) EtOH, 0.5% (v/v) acetic
acid (CH3COOH), stored at room temperature). They were shaken on a Belly Dancer
(Stovall Life Science, Inc) for 10 minutes to allow optimal covering of the gels by the
fixing solution. The fixing solution was discarded and the gels were rinsed twice (one
minute per rinse) with distilled water. All the water was discarded and the gels were
covered with freshly made staining solution (0.1% (w/v) silver nitrate (AgN03».
They were shaken on the Belly Dancer (Stovall Life Science, Inc) for a minimum of
ten minutes. The staining solution was discarded and the gels were rinsed once for
five seconds with distilled water. The water was discarded and the gels were covered
with cold developing solution (1.5% (w/v) sodium hydroxide (NaOH), 0.4% (v/v)
formaldehyde (HCHO) added just before use) and shaken on the Belly Dancer
(Stovall Life Science, Inc), allowing developing to continue for ten minutes or until
the gel turned yellow and red-brown bands of DNA were visible. The developing
solution was discarded and the gels were rinsed twice with distilled water. The gels
are stored in the dark in a plastic covering. Caution must be exercised not to touch the
gel with ones hands after the gel has been developed. All solutions after and
including the staining solution were discarded into well marked bottles for disposal.
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GENERAL SOLUTIONS
lXTBE
10.8mg/ml tris(hydroxymethyl)aminomethane ((CH20H)3CNH2-CI)
5.5mg/ml boric acid (H3B03)
0.7445mg/ml EDTA (CIOHI6N20g)
1.5XTBE
16.2mg/ml tris(hydroxymethyl)aminomethane ((CH20H)3CNH2-CI)
8.25mg/ml boric acid (H3B03)
1.116mg/ml EDTA (CIOHI6N20g)
6X Loading Dye
0.25% (w/v) bromophenol blue (CI9HIOBr40SS)
0.25% (w/v) xylene cyanol FF (C31H2gN2N~013S)
30.0% (w/v) glycerol (HOCH2CHOHCH20H)
Formamide Loading Dye
98% (v/v) formamide (H2NCHO)
10mM EDTA (CIOHI6N20g)
0.05% (w/v) bromophenol blue (CI9HIOBr40SS)
0.05% (w/v) xylene cyanol FF (C31H2gN2N~013S)
113
Stellenbosch University http://scholar.sun.ac.za
APPENDIXE
APPENDIXE
CYTOCHROME P450 POLYMORPHISM ANALYSIS
LI L2 LJ L4 L5 L6 L7
... 500 bp
Figure E.OI: A 3 % (w/v) agarose gel of the CYPIAlml polymorphism (MspI
restriction enzyme digest) in six of the Caucasian breast cancer patients
(LI-L3, L5-L7). Lanes 1,2, and 5 are individuals homozygous for the T-
allele, lanes 3 and 6 are individuals heterozygous for the polymorphism
(T/C genotype), while lane 7 is an individual homozygous for the C-
allele. Lane 4 contains a 100 bp ladder loaded as a molecular size
marker. The gel was stained in 0.0075% (v/v) EtBr.
LI L2 -JJ3 L4 L5
... 200 bp
Figure E.02: A 3 % (w/v) agarose gel of the CYPIAlm2 polymorphism (HindII
restriction enzyme digest) in four of the mixed ancestry controls (LI-L4).
Lanes 1, 2, and 3 are individuals homozygous for the A-allele, while lane
4 contains an individual heterozygous for the polymorphism (AlG
genotype). Lane 5 contains a 100 bp ladder loaded as a molecular size
marker. The gel was stained in 0.0075% (v/v) EtBr.
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500 bp ...
L2 LJ lA t."1 L8
Figure E.03: A 1 % agarose gel of the CYPIA2 polymorphism (Apa] restriction enzyme
digest) in 7 of the mixed ancestry controls (L2-L8). Lanes 2, 6, and 7 are
individuals homozygous for the A-allele, lanes 3, 4 and 8 are individuals
homozygous for the C-allele and lane 5 is an individual that is
heterozygous for the polymorphism (CIA genotype). Lane 1 contains a
100bp ladder loaded as a molecular size marker. The gel was stained in
0.0075% (v/v) EtBr.
L3. ~4 LS'
, .
Figure E.04: A 10% (v/v) urea SSCP polyacrylamide gel of the CYPIBI polymorphism
in five of the Caucasian controls (LI-L5). Lanes 1, 2, 3 and 4 are
individuals heterozygous for the polymorphism (CIA genotype), while
lane 5 contains an individual homozygous for the A-allele. The gel was
stained in 0.0075% (v/v) EtBr for visualisation of the bands.
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Figure E.05: A 15% (v/v) SSCP polyacrylamide gel of the CYP1B1 polymorphism in
three of the Caucasian controls (L1-L3). Lanes 1 and 2 are individuals
heterozygous for the polymorphism (CIA genotype), while lane 3
contains an individual homozygous for the A-allele. The gel was stained
in 0.0075% (v/v) EtBr for visualisation of the bands.
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C TT T AAA A TT CA T GAT AA A T CA TGG A AC CCC AC
a
ATAC TT TAAAATT CAT G ATAA CT CATG G AACCC
b
ACT T T AAA A TT CA T GAT A A M T CAT G G AACCCCA
t
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c
Figure E.06: Sequence outputs for the three possible genotypes for the CYP1B1
polymorphism. Figure E.06a indicates the homozygous A-allele state,
figure E.06b indicates the homozygous C-allele state and figure E.06c
indicates the heterozygous CIA state. PCR products were sequenced
using the CYP1B1F primer as described in Table 3.01 and Table 4.01.
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Figure E.07: A 15% (v/v) SSCP polyacrylamide gel of the CYP2D6*3 polymorphism in
five of the variegate porphyria patients (LI-L5). Lanes 1,2,3 and 5 are
individuals homozygous for the A-allele, while lane 4 contains an
individual heterozygous for the polymorphism (Aldel genotype). The gel
was silver stained for visualisation of the bands.
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300 bp
Figure E.08: A 3% (w/v) agarose gel of the CYP2D6*4 polymorphism (MvaI/BstNI
restriction enzyme digest) in five of the variegate porphyria patients (Ll-
L5). Lanes 1,3 and 5 are individuals homozygous for the G-allele, while
lanes 2 and 4 contain individuals heterozygous for the polymorphism
(G/A genotype). Lane 6 contains a 100 bp ladder which served as a
molecular size marker. The gel was stained in 0.0075% (v/v) EtBr for
visualisation of the bands.
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